<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Nutrients</journal-id><journal-id journal-id-type="iso-abbrev">Nutrients</journal-id><journal-id journal-id-type="publisher-id">nutrients</journal-id><journal-title-group><journal-title>Nutrients</journal-title></journal-title-group><issn pub-type="epub">2072-6643</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29439405</article-id><article-id pub-id-type="pmc">5852772</article-id><article-id pub-id-type="doi">10.3390/nu10020196</article-id><article-id pub-id-type="publisher-id">nutrients-10-00196</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Cai-Mei</given-names></name><xref ref-type="aff" rid="af1-nutrients-10-00196">1</xref><xref ref-type="aff" rid="af2-nutrients-10-00196">2</xref><xref ref-type="aff" rid="af3-nutrients-10-00196">3</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Chia-Chao</given-names></name><xref ref-type="aff" rid="af4-nutrients-10-00196">4</xref></contrib><contrib contrib-type="author"><name><surname>Hung</surname><given-names>Chi-Feng</given-names></name><xref ref-type="aff" rid="af5-nutrients-10-00196">5</xref><xref ref-type="aff" rid="af6-nutrients-10-00196">6</xref></contrib><contrib contrib-type="author"><name><surname>Liao</surname><given-names>Min-Tser</given-names></name><xref ref-type="aff" rid="af7-nutrients-10-00196">7</xref><xref ref-type="aff" rid="af8-nutrients-10-00196">8</xref></contrib><contrib contrib-type="author"><name><surname>Shyu</surname><given-names>Jia-Fwu</given-names></name><xref ref-type="aff" rid="af9-nutrients-10-00196">9</xref></contrib><contrib contrib-type="author"><name><surname>Hsu</surname><given-names>Yung-Ho</given-names></name><xref ref-type="aff" rid="af1-nutrients-10-00196">1</xref><xref ref-type="aff" rid="af2-nutrients-10-00196">2</xref><xref ref-type="aff" rid="af3-nutrients-10-00196">3</xref></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Chien-Lin</given-names></name><xref ref-type="aff" rid="af1-nutrients-10-00196">1</xref><xref ref-type="aff" rid="af10-nutrients-10-00196">10</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Yuan-Hung</given-names></name><xref ref-type="aff" rid="af1-nutrients-10-00196">1</xref><xref ref-type="aff" rid="af11-nutrients-10-00196">11</xref></contrib><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Jing-Quan</given-names></name><xref ref-type="aff" rid="af1-nutrients-10-00196">1</xref><xref ref-type="aff" rid="af12-nutrients-10-00196">12</xref></contrib><contrib contrib-type="author"><name><surname>Chang</surname><given-names>Tian-Jong</given-names></name><xref ref-type="aff" rid="af13-nutrients-10-00196">13</xref><xref ref-type="aff" rid="af14-nutrients-10-00196">14</xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Yuh-Feng</given-names></name><xref ref-type="aff" rid="af1-nutrients-10-00196">1</xref><xref ref-type="aff" rid="af2-nutrients-10-00196">2</xref><xref ref-type="aff" rid="af3-nutrients-10-00196">3</xref><xref rid="c1-nutrients-10-00196" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Kuo-Cheng</given-names></name><xref ref-type="aff" rid="af1-nutrients-10-00196">1</xref><xref ref-type="aff" rid="af10-nutrients-10-00196">10</xref><xref rid="c1-nutrients-10-00196" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-nutrients-10-00196"><label>1</label>Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan; <email>11044@s.tmu.edu.tw</email> (C.-M.Z.); <email>yhhsu@s.tmu.edu.tw</email> (Y.-H.H.); <email>janlin0123@gmail.com</email> (C.-L.L.); <email>12072@s.tmu.edu.tw</email> (Y.-H.W.); <email>jingquan235@gmail.com</email> (J.-Q.Z.)</aff><aff id="af2-nutrients-10-00196"><label>2</label>Division of Nephrology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City 235, Taiwan</aff><aff id="af3-nutrients-10-00196"><label>3</label>Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan</aff><aff id="af4-nutrients-10-00196"><label>4</label>Division of Nephrology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan; <email>wucc@ndmctsgh.edu.tw</email></aff><aff id="af5-nutrients-10-00196"><label>5</label>School of Medicine, Fu-Jen Catholic University, New Taipei City 242, Taiwan; <email>054317@gmail.com</email></aff><aff id="af6-nutrients-10-00196"><label>6</label>Graduate Institute of Biomedical and Pharmaceutical Science, Fu-Jen Catholic University, New Taipei City 242, Taiwan</aff><aff id="af7-nutrients-10-00196"><label>7</label>Department of Pediatrics, Taoyuan Armed Forces General Hospital, Taoyuan 325, Taiwan; <email>liaoped804h@yahoo.com.tw</email></aff><aff id="af8-nutrients-10-00196"><label>8</label>Division of Pediatrics, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan</aff><aff id="af9-nutrients-10-00196"><label>9</label>Department of Biology and Anatomy, National Defense Medical Center, Taipei 114, Taiwan; <email>shyujeff@mail.ndmctsgh.edu.tw</email></aff><aff id="af10-nutrients-10-00196"><label>10</label>Division of Nephrology, Department of Medicine, Cardinal-Tien Hospital &amp; Fu-Jen Catholic University Hospital, School of Medicine, Fu-Jen Catholic University, New Taipei City 242, Taiwan</aff><aff id="af11-nutrients-10-00196"><label>11</label>Department of Medical Research, Shuang Ho Hospital, Taipei Medical University, New Taipei City 235, Taiwan</aff><aff id="af12-nutrients-10-00196"><label>12</label>Division of Critical Care, Department of Critical Care Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City 235, Taiwan</aff><aff id="af13-nutrients-10-00196"><label>13</label>Graduate Institute of Life Sciences, National Defense Medical Center, Taipei 114, Taiwan; <email>10247@s.tmu.edu.tw</email></aff><aff id="af14-nutrients-10-00196"><label>14</label>Performance Appraisal Section, Secretary Office, Shuang Ho Hospital, Taipei Medical University, Taipei 235, Taiwan</aff><author-notes><corresp id="c1-nutrients-10-00196"><label>*</label>Correspondence: <email>linyf@shh.org.tw</email> (Y.-F.L.); <email>kuochenglu@gmail.com</email> (K.-C.L.)</corresp></author-notes><pub-date pub-type="epub"><day>10</day><month>2</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2018</year></pub-date><volume>10</volume><issue>2</issue><elocation-id>196</elocation-id><history><date date-type="received"><day>18</day><month>1</month><year>2018</year></date><date date-type="accepted"><day>08</day><month>2</month><year>2018</year></date></history><permissions><copyright-statement>© 2018 by the authors.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><offsets xml_i="8040" xml_f="9130" txt_i="11" txt_f="1095">We evaluated the improvement of intact parathyroid hormone (iPTH) levels and bone parameters by supplementing nutritional vitamin D (cholecalciferol) to combined calcimimetic (cinacalcet) and active vitamin D analog (calcitriol) among severe secondary hyperparathyroidism (SHPT) hemodialysis (HD) patients. A randomized, controlled open-label study was undertaken in 60 HD patients with serum iPTH &gt; 1000 pg/mL or persistently high iPTH ≥ 600 pg/mL even after &gt;3 months of calcitriol (3 μg/week). The study group received oral cholecalciferol (5000 IU/ day) and the control group received a placebo. All patients received fixed dose cinacalcet (30 mg/day, orally) and calcitriol. Calcitriol was reduced if iPTH ≤ 300 pg/mL and cinacalcet was withdrawn if serum iPTH was persistently low (iPTH ≤ 300 pg/mL) for 4 weeks after the reduction of calcitriol. A significantly lower iPTH level was noted from the 20th week in the study group compared to the placebo group, and the target iPTH ≤ 300 pg/mL was achieved at the 24th week in the study group. Most patients achieved serum 25-(OH)D</offsets><sub><offsets xml_i="9135" xml_f="9136" txt_i="1095" txt_f="1096">3</offsets></sub><offsets xml_i="9142" xml_f="9367" txt_i="1096" txt_f="1318"> ≥ 30 ng/mL in the study group. Nearly 40% of study patients gained &gt;10% improvement in femoral neck (FN) bone mineral density (BMD). We conclude that cholecalciferol additively reduced serum iPTH levels, improved 25-(OH)D</offsets><sub><offsets xml_i="9372" xml_f="9373" txt_i="1318" txt_f="1319">3</offsets></sub><offsets xml_i="9379" xml_f="9480" txt_i="1319" txt_f="1420"> levels and improved FN BMD when used together with cinacalcet/calcitriol in severe SHPT HD patients.</offsets></p></abstract><kwd-group><kwd>cholecalciferol</kwd><kwd>hemodialysis</kwd><kwd>secondary hyperparathyroidism</kwd><kwd>cinacalcet</kwd><kwd>calcitriol</kwd></kwd-group></article-meta></front><body><sec id="sec1-nutrients-10-00196"><title><offsets xml_i="9719" xml_f="9734" txt_i="1428" txt_f="1443">1. Introduction</offsets></title><p><offsets xml_i="9745" xml_f="9899" txt_i="1444" txt_f="1598">Secondary hyperparathyroidism (SHPT) is a major complication among dialysis patients which can have renal osteodystrophy and cardiovascular consequences [</offsets><xref rid="B1-nutrients-10-00196" ref-type="bibr"><offsets xml_i="9949" xml_f="9950" txt_i="1598" txt_f="1599">1</offsets></xref><offsets xml_i="9957" xml_f="9958" txt_i="1599" txt_f="1600">,</offsets><xref rid="B2-nutrients-10-00196" ref-type="bibr"><offsets xml_i="10008" xml_f="10009" txt_i="1600" txt_f="1601">2</offsets></xref><offsets xml_i="10016" xml_f="10502" txt_i="1601" txt_f="2087">]. Dietary control, phosphate binders and active vitamin D analogs are used in earlier SHPT whereas calcimimetic agent, cinacalcet, is indicated in later stages of SHPT cases who have markedly elevated parathyroid hormone (PTH) levels or failed to respond earlier treatment. The doses of active vitamin D analogs are reduced or cinacalcet is added when the patients have progressively high calcium, phosphate and Ca × P products to prevent cardiovascular and soft-tissue calcification [</offsets><xref rid="B3-nutrients-10-00196" ref-type="bibr"><offsets xml_i="10552" xml_f="10553" txt_i="2087" txt_f="2088">3</offsets></xref><offsets xml_i="10560" xml_f="10561" txt_i="2088" txt_f="2089">,</offsets><xref rid="B4-nutrients-10-00196" ref-type="bibr"><offsets xml_i="10611" xml_f="10612" txt_i="2089" txt_f="2090">4</offsets></xref><offsets xml_i="10619" xml_f="10824" txt_i="2090" txt_f="2295">]. Many studies demonstrated that cinacalcet improves PTH control and achieves recommended serum calcium and phosphorus values when used in combination with active vitamin D analogs and phosphate binders [</offsets><xref rid="B5-nutrients-10-00196" ref-type="bibr"><offsets xml_i="10874" xml_f="10875" txt_i="2295" txt_f="2296">5</offsets></xref><offsets xml_i="10882" xml_f="10883" txt_i="2296" txt_f="2297">,</offsets><xref rid="B6-nutrients-10-00196" ref-type="bibr"><offsets xml_i="10933" xml_f="10934" txt_i="2297" txt_f="2298">6</offsets></xref><offsets xml_i="10941" xml_f="10942" txt_i="2298" txt_f="2299">,</offsets><xref rid="B7-nutrients-10-00196" ref-type="bibr"><offsets xml_i="10992" xml_f="10993" txt_i="2299" txt_f="2300">7</offsets></xref><offsets xml_i="11000" xml_f="11001" txt_i="2300" txt_f="2301">,</offsets><xref rid="B8-nutrients-10-00196" ref-type="bibr"><offsets xml_i="11051" xml_f="11052" txt_i="2301" txt_f="2302">8</offsets></xref><offsets xml_i="11059" xml_f="11060" txt_i="2302" txt_f="2303">,</offsets><xref rid="B9-nutrients-10-00196" ref-type="bibr"><offsets xml_i="11110" xml_f="11111" txt_i="2303" txt_f="2304">9</offsets></xref><offsets xml_i="11118" xml_f="11315" txt_i="2304" txt_f="2501">]. In our previous study, we revealed additional PTH lowering and anti-inflammatory effects of nutritional vitamin D (cholecalciferol) supplementation to active vitamin D analogs in SHPT patients [</offsets><xref rid="B10-nutrients-10-00196" ref-type="bibr"><offsets xml_i="11366" xml_f="11368" txt_i="2501" txt_f="2503">10</offsets></xref><offsets xml_i="11375" xml_f="11543" txt_i="2503" txt_f="2671">]. However, data regarding the addition of cholecalciferol supplementation to combined cinacalcet and active vitamin D analogs in severe SHPT patients is still lacking.</offsets></p><p><offsets xml_i="11550" xml_f="11630" txt_i="2672" txt_f="2752">Circulating PTH levels were found to be inversely correlated with serum 25(OH) D</offsets><sub><offsets xml_i="11635" xml_f="11636" txt_i="2752" txt_f="2753">3</offsets></sub><offsets xml_i="11642" xml_f="11717" txt_i="2753" txt_f="2828">, a circulating vitamin D metabolite which indicated the vitamin D status [</offsets><xref rid="B11-nutrients-10-00196" ref-type="bibr"><offsets xml_i="11768" xml_f="11770" txt_i="2828" txt_f="2830">11</offsets></xref><offsets xml_i="11777" xml_f="11778" txt_i="2830" txt_f="2831">,</offsets><xref rid="B12-nutrients-10-00196" ref-type="bibr"><offsets xml_i="11829" xml_f="11831" txt_i="2831" txt_f="2833">12</offsets></xref><offsets xml_i="11838" xml_f="11848" txt_i="2833" txt_f="2843">]. 25(OH)D</offsets><sub><offsets xml_i="11853" xml_f="11854" txt_i="2843" txt_f="2844">3</offsets></sub><offsets xml_i="11860" xml_f="11924" txt_i="2844" txt_f="2908"> was an important substrate for the local generation of 1,25(OH)</offsets><sub><offsets xml_i="11929" xml_f="11930" txt_i="2908" txt_f="2909">2</offsets></sub><offsets xml_i="11936" xml_f="11997" txt_i="2909" txt_f="2970">D with the help of local 1α-hydroxylase (1α-OHase) activity [</offsets><xref rid="B13-nutrients-10-00196" ref-type="bibr"><offsets xml_i="12048" xml_f="12050" txt_i="2970" txt_f="2972">13</offsets></xref><offsets xml_i="12057" xml_f="12058" txt_i="2972" txt_f="2973">,</offsets><xref rid="B14-nutrients-10-00196" ref-type="bibr"><offsets xml_i="12109" xml_f="12111" txt_i="2973" txt_f="2975">14</offsets></xref><offsets xml_i="12118" xml_f="12187" txt_i="2975" txt_f="3044">]. Most end-stage renal disease (ESRD) patients had low serum 25(OH)D</offsets><sub><offsets xml_i="12192" xml_f="12193" txt_i="3044" txt_f="3045">3</offsets></sub><offsets xml_i="12199" xml_f="12208" txt_i="3045" txt_f="3054"> levels [</offsets><xref rid="B15-nutrients-10-00196" ref-type="bibr"><offsets xml_i="12259" xml_f="12261" txt_i="3054" txt_f="3056">15</offsets></xref><offsets xml_i="12268" xml_f="12269" txt_i="3056" txt_f="3057">,</offsets><xref rid="B16-nutrients-10-00196" ref-type="bibr"><offsets xml_i="12320" xml_f="12322" txt_i="3057" txt_f="3059">16</offsets></xref><offsets xml_i="12329" xml_f="12350" txt_i="3059" txt_f="3080">]. Segersten et al. [</offsets><xref rid="B17-nutrients-10-00196" ref-type="bibr"><offsets xml_i="12401" xml_f="12403" txt_i="3080" txt_f="3082">17</offsets></xref><offsets xml_i="12410" xml_f="12708" txt_i="3082" txt_f="3380">] revealed 1α-OHase expression in parathyroid glands which presumably suppressed the PTH gland hyperplasia in an autocrine/paracrine manner. Previous research revealed coincident increased expression of 1α-OHase (approximately increased in 10 folds) and reduced 24-hydroxylase in most SHPT glands [</offsets><xref rid="B18-nutrients-10-00196" ref-type="bibr"><offsets xml_i="12759" xml_f="12761" txt_i="3380" txt_f="3382">18</offsets></xref><offsets xml_i="12768" xml_f="12817" txt_i="3382" txt_f="3431">] and highlighted the requirement of more 25(OH)D</offsets><sub><offsets xml_i="12822" xml_f="12823" txt_i="3431" txt_f="3432">3</offsets></sub><offsets xml_i="12829" xml_f="12867" txt_i="3432" txt_f="3470"> in these patients. CS Ritter et al. [</offsets><xref rid="B19-nutrients-10-00196" ref-type="bibr"><offsets xml_i="12918" xml_f="12920" txt_i="3470" txt_f="3472">19</offsets></xref><offsets xml_i="12927" xml_f="12968" txt_i="3472" txt_f="3513">] proved that the local effect of 25(OH)D</offsets><sub><offsets xml_i="12973" xml_f="12974" txt_i="3513" txt_f="3514">3</offsets></sub><offsets xml_i="12980" xml_f="13117" txt_i="3514" txt_f="3651"> on PTH suppression possibly occurs through direct activation of the vitamin D receptor (VDR) in parathyroid glands. Furthermore, 25(OH)D</offsets><sub><offsets xml_i="13122" xml_f="13123" txt_i="3651" txt_f="3652">3</offsets></sub><offsets xml_i="13129" xml_f="13326" txt_i="3652" txt_f="3849"> played less role in systemic hypercalcemia and related complications. These findings explain the possible additive role of nutritional vitamin D (cholecalciferol) supplementation in SHPT patients.</offsets></p><p><offsets xml_i="13333" xml_f="13468" txt_i="3850" txt_f="3985">Among two types of parathyroid cells (chief cells (CC) and oxyphil cells (OC)), OC markedly increased in chronic kidney disease (CKD) [</offsets><xref rid="B20-nutrients-10-00196" ref-type="bibr"><offsets xml_i="13519" xml_f="13521" txt_i="3985" txt_f="3987">20</offsets></xref><offsets xml_i="13528" xml_f="13638" txt_i="3987" txt_f="4097">]. Lomonte C et al. revealed calcitriol therapy significantly increases the OC content in parathyroid glands [</offsets><xref rid="B21-nutrients-10-00196" ref-type="bibr"><offsets xml_i="13689" xml_f="13691" txt_i="4097" txt_f="4099">21</offsets></xref><offsets xml_i="13698" xml_f="13815" txt_i="4099" txt_f="4216">]. Cinacalcet acts through CaR in the CC of parathyroid glands and exerts antiproliferative and proapoptotic action [</offsets><xref rid="B22-nutrients-10-00196" ref-type="bibr"><offsets xml_i="13866" xml_f="13868" txt_i="4216" txt_f="4218">22</offsets></xref><offsets xml_i="13875" xml_f="13876" txt_i="4218" txt_f="4219">,</offsets><xref rid="B23-nutrients-10-00196" ref-type="bibr"><offsets xml_i="13927" xml_f="13929" txt_i="4219" txt_f="4221">23</offsets></xref><offsets xml_i="13936" xml_f="14043" txt_i="4221" txt_f="4328">]. Studies revealed that cinacalcet significantly increases the OC/CC ratio (approx. increase 3.42 times) [</offsets><xref rid="B24-nutrients-10-00196" ref-type="bibr"><offsets xml_i="14094" xml_f="14096" txt_i="4328" txt_f="4330">24</offsets></xref><offsets xml_i="14103" xml_f="14137" txt_i="4330" txt_f="4364">] and increases the oxyphil area [</offsets><xref rid="B25-nutrients-10-00196" ref-type="bibr"><offsets xml_i="14188" xml_f="14190" txt_i="4364" txt_f="4366">25</offsets></xref><offsets xml_i="14197" xml_f="14287" txt_i="4366" txt_f="4456">]. These OC excessively express 1α OHase enzyme and increase local calcitriol production [</offsets><xref rid="B26-nutrients-10-00196" ref-type="bibr"><offsets xml_i="14338" xml_f="14340" txt_i="4456" txt_f="4458">26</offsets></xref><offsets xml_i="14347" xml_f="14681" txt_i="4458" txt_f="4792">], which further carries out autocrine/paracrine regulation of PTH synthesis and release. Thus, cinacalcet use further increases the requirement of substrate chocalciferol for 1α OHase to produce local calcitriol production in OC. Calcimimetics also up-regulate decreased parathyroid CaR and VDR in both in vitro and in vivo studies [</offsets><xref rid="B27-nutrients-10-00196" ref-type="bibr"><offsets xml_i="14732" xml_f="14734" txt_i="4792" txt_f="4794">27</offsets></xref><offsets xml_i="14741" xml_f="14742" txt_i="4794" txt_f="4795">,</offsets><xref rid="B28-nutrients-10-00196" ref-type="bibr"><offsets xml_i="14793" xml_f="14795" txt_i="4795" txt_f="4797">28</offsets></xref><offsets xml_i="14802" xml_f="14853" txt_i="4797" txt_f="4848">] which further mediates parathyroid proliferation.</offsets></p><p><offsets xml_i="14860" xml_f="15069" txt_i="4849" txt_f="5058">Therefore, we speculate that combining cinacalcet to calcitriol therapy increases the parathyroid OC/CC ratio, increases local 1αOHase activity, and increases VDR expression which additively needs more 25(OH)D</offsets><sub><offsets xml_i="15074" xml_f="15075" txt_i="5058" txt_f="5059">3</offsets></sub><offsets xml_i="15081" xml_f="15497" txt_i="5059" txt_f="5475"> for local calcitriol synthesis. We hypothesize that the cholecalciferol supplementation in SHPT patients together with calcitriol and cinacalcet therapy increase local calcitriol production, which further suppresses intact parathyroid hormone (iPTH) secretion. We further describe the changes in bone turnover markers and bone densities with or without cholecalciferol supplementation in SHPT hemodialysis patients.</offsets></p></sec><sec id="sec2-nutrients-10-00196"><title><offsets xml_i="15548" xml_f="15572" txt_i="5477" txt_f="5501">2. Materials and Methods</offsets></title><sec id="sec2dot1-nutrients-10-00196"><title><offsets xml_i="15625" xml_f="15642" txt_i="5502" txt_f="5519">2.1. Study Design</offsets></title><p><offsets xml_i="15653" xml_f="16184" txt_i="5520" txt_f="6051">The trial was designed as a randomized, controlled open-label study. A total of 80 patients were eligible and agreed to participate. Group matching with gender, age (within 5 years), and duration of hemodialysis (within 1 year) was conducted for every pair group and they were then randomly assigned to either treatment with cinacalcet, calcitriol and cholecalciferol (CCC, study group) or control group, treated with cinacalcet, calcitriol and placebo (CCP, control group). G*power was used to calculate the required sample size [</offsets><xref rid="B29-nutrients-10-00196" ref-type="bibr"><offsets xml_i="16235" xml_f="16237" txt_i="6051" txt_f="6053">29</offsets></xref><offsets xml_i="16244" xml_f="16624" txt_i="6053" txt_f="6433">] and effects were detected in a two-sided test with a power of (1 − β) = 80% at a significance level of 0.05. Other calculation settings were as follows: (1) the randomization process was based on 1:1 proportion of this study; (2) the effect size was set as 0.8. The required sample size for calculating was at least 25 subjects in the CCC group and 25 subjects in the CCP group.</offsets></p></sec><sec id="sec2dot2-nutrients-10-00196"><title><offsets xml_i="16679" xml_f="16721" txt_i="6435" txt_f="6477">2.2. Patient Eligibility and Randomization</offsets></title><p><offsets xml_i="16732" xml_f="17883" txt_i="6478" txt_f="7626">Patients aged above 18 years treated with maintenance hemodialysis three times per week for at least 3 months before screening were eligible. Patients with severe SHPT (serum iPTH &gt; 1000 pg/mL or persistantly high serum iPTH ≥ 600 pg/mL even after more than 3 months of calcitriol treatment) were enrolled. All patients needed to stop receiving an active vitamin D at least 30 days before entering the study. Patients using calcimimetic agents and/or native vitamin D analogs were excluded. The patients were excluded if they were pregnant, breastfeeding or of childbearing potential and not practicing birth control. Those with malignancies, severe malnutrition, and inflammatory or infectious disorders diagnosed for more than 3 months before the study were also excluded. Other exclusion criteria included surgical interventions and vascular diseases, including acute coronary syndrome, unstable angina, cerebrovascular accident, transient ischemic attack, deep vein thrombosis, pulmonary embolism, or congestive heart failure within 3 months of the study period. The patients were also excluded if they had a history of allergy to medications (</offsets><xref ref-type="fig" rid="nutrients-10-00196-f001"><offsets xml_i="17934" xml_f="17942" txt_i="7626" txt_f="7634">Figure 1</offsets></xref><offsets xml_i="17949" xml_f="18054" txt_i="7634" txt_f="7739">). Sixty hemodialysis (HD) patients fulfilled the criteria and were randomized into the CCC study group (</offsets><italic><offsets xml_i="18062" xml_f="18063" txt_i="7739" txt_f="7740">N</offsets></italic><offsets xml_i="18072" xml_f="18102" txt_i="7740" txt_f="7770"> = 30) and CCP control group (</offsets><italic><offsets xml_i="18110" xml_f="18111" txt_i="7770" txt_f="7771">N</offsets></italic><offsets xml_i="18120" xml_f="18180" txt_i="7771" txt_f="7831"> = 30). Patients were well matched by treatment allocation (</offsets><xref ref-type="fig" rid="nutrients-10-00196-f001"><offsets xml_i="18231" xml_f="18239" txt_i="7831" txt_f="7839">Figure 1</offsets></xref><offsets xml_i="18246" xml_f="18504" txt_i="7839" txt_f="8097">). Protocol and informed consent were approved by the authorities of the Institutional Review Board of Cardinal Tien Hospital and Taipei Medical University (CTH106A-2B01 and CTH-104-3-5-022). All the patients provided written consent before study enrollment.</offsets></p></sec><sec id="sec2dot3-nutrients-10-00196"><title><offsets xml_i="18559" xml_f="18586" txt_i="8099" txt_f="8126">2.3. Treatment Intervention</offsets></title><p><offsets xml_i="18597" xml_f="18994" txt_i="8127" txt_f="8521">All patients were given oral cinacalcet (30 mg/day) from the start of the study. Patients in the study group were given an oral form of cholecalciferol 5000 IU per day (Healthy Origens, Pittsburgh, PA 15241, USA); and cholecalciferol placebo (olive oil) was given in the control group. During the treatment, the calcitriol dose could be decreased when iPTH was ≤ 300 pg/mL and Ca × P was &gt;55 mg</offsets><sup><offsets xml_i="18999" xml_f="19000" txt_i="8521" txt_f="8522">2</offsets></sup><offsets xml_i="19006" xml_f="19009" txt_i="8522" txt_f="8525">/dl</offsets><sup><offsets xml_i="19014" xml_f="19015" txt_i="8525" txt_f="8526">2</offsets></sup><offsets xml_i="19021" xml_f="20137" txt_i="8526" txt_f="9636">. The doses of Ca-based and other phosphate binders could be adjusted throughout the study. Ca-based phosphate binders could be increased when the serum Ca was &lt;8.4 mg/dL or the patient had symptoms of hypocalcemia. Cinacalcet was given in a fixed low dose (30 mg/day) during the whole study period, and was withdrawn if the serum iPTH was persistently low (iPTH ≤ 300 pg/mL) for 4 weeks after the reduction of calcitriol or serum calcium &lt;8.4 mg/dl or the patient had symptoms of hypocalcemia. All patients used low dialysate Ca 2.5 mEq/L and adjusted according to serum Ca levels throughout the study. A baseline visit was performed just before the start of the study, and further study visits were performed at 4, 8, 12, 16, 20 and 24 weeks after the medication. Serum biochemical parameters and bone turnover markers were assessed at baseline and during follow-up. The femoral neck (FN) and lumbar spine (LS) bone mineral density (BMD) were determined by dual X-ray absorptiometry (DXA) before and at the end of the study period. Hospital records were obtained and examined by two practicing nephrologists.</offsets></p></sec><sec id="sec2dot4-nutrients-10-00196"><title><offsets xml_i="20192" xml_f="20245" txt_i="9638" txt_f="9691">2.4. Serum Biochemical and Bone Metabolism Parameters</offsets></title><p><offsets xml_i="20256" xml_f="20402" txt_i="9692" txt_f="9838">Blood samples were collected and serum was separated within 1 h of collection and immediately frozen until analysis. Serum levels of iPTH, 25(OH)D</offsets><sub><offsets xml_i="20407" xml_f="20408" txt_i="9838" txt_f="9839">3</offsets></sub><offsets xml_i="20414" xml_f="20628" txt_i="9839" txt_f="10053">, phosphorus, calcium and other bone metabolism parameters were determined. Serum iPTH levels were measured in an immunoradiometric assay (Nichols Institute Diagnostics, San Juan Capistrano, CA, USA). Serum 25(OH)D</offsets><sub><offsets xml_i="20633" xml_f="20634" txt_i="10053" txt_f="10054">3</offsets></sub><offsets xml_i="20640" xml_f="21035" txt_i="10054" txt_f="10449"> was determined by enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s instructions (Immundiagnostik AG, Bensheim, Germany). Serum bone specific alkaline phosphatase (BAP), a marker of bone formation was determined by ELISA (Quidel, Inc., San Diego, CA, USA); whereas tartrate-resistant acid phosphatase (TRACP)-5b, a marker of bone resorption was measured by ELISA (Quidel</offsets><sup><offsets xml_i="21040" xml_f="21041" txt_i="10449" txt_f="10450">®</offsets></sup><offsets xml_i="21047" xml_f="21295" txt_i="10450" txt_f="10698">, Tecomedical Group, Sissach, Switzerland). The doses of calcitriol, cinacalcet and phosphate binders were recorded at each visit. Adverse events were collected from patients’ reports and in response to non-directed questioning at each study visit.</offsets></p></sec><sec id="sec2dot5-nutrients-10-00196"><title><offsets xml_i="21350" xml_f="21391" txt_i="10700" txt_f="10741">2.5. Objectives and Outcomes and Measures</offsets></title><p><offsets xml_i="21402" xml_f="21474" txt_i="10742" txt_f="10814">Our study used the Kidney Disease Outcomes Quality Initiative (K/DOQI) [</offsets><xref rid="B30-nutrients-10-00196" ref-type="bibr"><offsets xml_i="21525" xml_f="21527" txt_i="10814" txt_f="10816">30</offsets></xref><offsets xml_i="21534" xml_f="21535" txt_i="10816" txt_f="10817">,</offsets><xref rid="B31-nutrients-10-00196" ref-type="bibr"><offsets xml_i="21586" xml_f="21588" txt_i="10817" txt_f="10819">31</offsets></xref><offsets xml_i="21595" xml_f="21959" txt_i="10819" txt_f="11183">] targeted bone metabolism levels; serum Ca 8.4–9.5 mg/dL, P 3.5–5.5 mg/dL, iPTH 150–300 pg/mL. Interpretation of DXA scans using lumbar spine BMD was not precise in our patients since it might have been interfered with by aorta calcification and degenerative joint diseases. Thus, we used 10% improvement in femoral BMD instead of lumbar spine BMD as our outcome.</offsets></p><p><offsets xml_i="21966" xml_f="22039" txt_i="11184" txt_f="11257">Primary Outcome: The primary outcome measure was serum iPTH ≤ 300 pg/mL. </offsets></p><p><offsets xml_i="22046" xml_f="22115" txt_i="11258" txt_f="11327">Secondary Outcome: The secondary outcome measures were serum 25-(OH)D</offsets><sub><offsets xml_i="22120" xml_f="22121" txt_i="11327" txt_f="11328">3</offsets></sub><offsets xml_i="22127" xml_f="22193" txt_i="11328" txt_f="11394"> ≥ 30 ng/mL and 10% improvement in femoral neck BMD from baseline.</offsets></p></sec><sec id="sec2dot6-nutrients-10-00196"><title><offsets xml_i="22248" xml_f="22293" txt_i="11396" txt_f="11441">2.6. Data Collection and Statistical Analysis</offsets></title><p><offsets xml_i="22304" xml_f="22759" txt_i="11442" txt_f="11897">The results were expressed as mean ± standard deviation or median (interquartile range). Parametric or non-parametric tests were used for analysis; for paired data, the Student t or Wilcoxon tests, respectively, and for between-group comparisons, the Student t, one-way ANOVA or Mann–Whitney U tests were used. Unilateral correlation analysis was performed using Pearson (r) or Spearman correlation (rs), as appropriate. All the tests were two-sided, and </offsets><italic><offsets xml_i="22767" xml_f="22768" txt_i="11897" txt_f="11898">p</offsets></italic><offsets xml_i="22777" xml_f="22942" txt_i="11898" txt_f="12060"> &lt; 0.05 was considered statistically significant. Statistica (Version 11, Stat Soft, Inc., 2300 East 14th Street, Tulsa, OK 74104, USA) was used for calculations.</offsets></p></sec></sec><sec id="sec3-nutrients-10-00196"><title><offsets xml_i="22999" xml_f="23009" txt_i="12063" txt_f="12073">3. Results</offsets></title><sec id="sec3dot1-nutrients-10-00196"><title><offsets xml_i="23062" xml_f="23104" txt_i="12074" txt_f="12116">3.1. Patient Recruitment and Analysis Sets</offsets></title><p><xref ref-type="table" rid="nutrients-10-00196-t001"><offsets xml_i="23168" xml_f="23175" txt_i="12117" txt_f="12124">Table 1</offsets></xref><offsets xml_i="23182" xml_f="23674" txt_i="12124" txt_f="12613"> shows the demographic characteristics of the study patients. All the patients were under HD with severe SHPT (serum iIPTH &gt; 1000 pg/mL) or persistently high SHPT (serum iIPTH ≥ 600 pg/mL) even with 3 months of calcitriol treatment. Dialysis vintage, body mass index (BMI), underlying etiologies of ESRD and prior calcitriol usage were not significantly differing between two groups. All patients had high serum iPTH levels [CCC, 1034 ± 270 pg/mL vs. CCP, 1016 ± 252 pg/mL] and low 25(OH)D</offsets><sub><offsets xml_i="23679" xml_f="23680" txt_i="12613" txt_f="12614">3</offsets></sub><offsets xml_i="23686" xml_f="23815" txt_i="12614" txt_f="12743"> levels [CCC, 18.2 ± 8.4 ng/mL vs. CCP, 19.2 ± 7.4 ng/mL]. Serum albumin, ALP, cCa and P levels were not significantly different.</offsets></p></sec><sec id="sec3dot2-nutrients-10-00196"><title><offsets xml_i="23870" xml_f="23956" txt_i="12745" txt_f="12831">3.2. Changes in Serum Intact Parathyroid Hormone (iPTH) Levels during the Study Period</offsets></title><p><offsets xml_i="23967" xml_f="24078" txt_i="12832" txt_f="12943">At 24 weeks, an average target iPTH level (≤300 pg/mL) was achieved in the CCC group but not in the CCP group (</offsets><xref ref-type="table" rid="nutrients-10-00196-t002"><offsets xml_i="24131" xml_f="24138" txt_i="12943" txt_f="12950">Table 2</offsets></xref><offsets xml_i="24145" xml_f="24350" txt_i="12950" txt_f="13155">). The serum iPTH levels were significantly lower in the CCC group compared to the CCP group from the 20th week of the study, 336.4 ± 124.1 pg/mL in the CCC group vs. 404.4 ± 107.0 pg/mL in the CCP group (</offsets><italic><offsets xml_i="24358" xml_f="24359" txt_i="13155" txt_f="13156">p</offsets></italic><offsets xml_i="24368" xml_f="24392" txt_i="13156" txt_f="13180"> = 0.034) at 20th week (</offsets><xref ref-type="table" rid="nutrients-10-00196-t003"><offsets xml_i="24445" xml_f="24452" txt_i="13180" txt_f="13187">Table 3</offsets></xref><offsets xml_i="24459" xml_f="24466" txt_i="13187" txt_f="13190"> &amp; </offsets><xref ref-type="fig" rid="nutrients-10-00196-f002"><offsets xml_i="24517" xml_f="24525" txt_i="13190" txt_f="13198">Figure 2</offsets></xref><offsets xml_i="24532" xml_f="24733" txt_i="13198" txt_f="13399">). The median changes in iPTH levels from baseline were significantly different as early as the 16th week of the study, −528.5 ± 148.1 pg/mL in the CCC group vs. −451.6 ± 116.0 pg/mL in the CCP group (</offsets><italic><offsets xml_i="24741" xml_f="24742" txt_i="13399" txt_f="13400">p</offsets></italic><offsets xml_i="24751" xml_f="24762" txt_i="13400" txt_f="13411"> = 0.036) (</offsets><xref ref-type="table" rid="nutrients-10-00196-t003"><offsets xml_i="24815" xml_f="24822" txt_i="13411" txt_f="13418">Table 3</offsets></xref><offsets xml_i="24829" xml_f="25097" txt_i="13418" txt_f="13683">). In subgroup analysis of the patients with severe vitamin D deficiency (25(OH)D3 &lt; 12.5 ng/mL), serum iPTH levels were significantly different between the two groups at the 12th week, 486.5 ± 203.9 pg/mL in the CCC group vs. 841.5 ± 209.1 pg/mL in the CCP group (</offsets><italic><offsets xml_i="25105" xml_f="25106" txt_i="13683" txt_f="13684">p</offsets></italic><offsets xml_i="25115" xml_f="25126" txt_i="13684" txt_f="13695"> = 0.024) (</offsets><xref ref-type="table" rid="nutrients-10-00196-t004"><offsets xml_i="25179" xml_f="25186" txt_i="13695" txt_f="13702">Table 4</offsets></xref><offsets xml_i="25193" xml_f="25338" txt_i="13702" txt_f="13847">). The target iPTH level (≤300 pg/mL) was achieved from the 20th week in the CCC group compared with the CCP group in this subgroup of patients (</offsets><xref ref-type="table" rid="nutrients-10-00196-t004"><offsets xml_i="25391" xml_f="25398" txt_i="13847" txt_f="13854">Table 4</offsets></xref><offsets xml_i="25405" xml_f="25544" txt_i="13854" txt_f="13993">). The mean dose of calcitriol use during the course of treatment was reduced progressively in the CCC group to control serum iPTH levels (</offsets><xref ref-type="table" rid="nutrients-10-00196-t005"><offsets xml_i="25597" xml_f="25604" txt_i="13993" txt_f="14000">Table 5</offsets></xref><offsets xml_i="25611" xml_f="25954" txt_i="14000" txt_f="14343">). Dialysate calcium and doses of phosphate binder use did not differ significantly between the groups (data not shown). We further found that 11.1%, 29.6%, 55.6% and 81.5% of the study CCC group and 7.1%, 10.7%, 14.3% and 25% of the control CCP group achieved the target iPTH level at the 12th, 16th, 18th, 20th and 24th weeks, respectively (</offsets><xref ref-type="table" rid="nutrients-10-00196-t006"><offsets xml_i="26007" xml_f="26014" txt_i="14343" txt_f="14350">Table 6</offsets></xref><offsets xml_i="26021" xml_f="26146" txt_i="14350" txt_f="14475">). Significantly more patients in the study group achieved the target level from the 20th week of the study (15/27 vs. 4/28, </offsets><italic><offsets xml_i="26154" xml_f="26155" txt_i="14475" txt_f="14476">p</offsets></italic><offsets xml_i="26164" xml_f="26201" txt_i="14476" txt_f="14513"> = 0.046 at 20th wk; 22/27 vs. 7/28, </offsets><italic><offsets xml_i="26209" xml_f="26210" txt_i="14513" txt_f="14514">p</offsets></italic><offsets xml_i="26219" xml_f="26259" txt_i="14514" txt_f="14554"> = 0.033 at 24th wk (chi-square test)) (</offsets><xref ref-type="table" rid="nutrients-10-00196-t006"><offsets xml_i="26312" xml_f="26319" txt_i="14554" txt_f="14561">Table 6</offsets></xref><offsets xml_i="26326" xml_f="26467" txt_i="14561" txt_f="14699">). Most of our patients tolerated 30 mg of cinacalcet and none of the patients had hypocalcemia (cCa &lt; 8.4 mg/dL) during the study period.</offsets></p></sec><sec id="sec3dot3-nutrients-10-00196"><title><offsets xml_i="26522" xml_f="26583" txt_i="14701" txt_f="14762">3.3. Changes in Serum 25(OH)D3 Levels during the Study Period</offsets></title><p><offsets xml_i="26594" xml_f="26619" txt_i="14763" txt_f="14788">In the CCC group, 25(OH)D</offsets><sub><offsets xml_i="26624" xml_f="26625" txt_i="14788" txt_f="14789">3</offsets></sub><offsets xml_i="26631" xml_f="26694" txt_i="14789" txt_f="14852"> levels increased significantly from 18.2 ± 8.4 to 37.4 ± 9.6 (</offsets><italic><offsets xml_i="26702" xml_f="26703" txt_i="14852" txt_f="14853">p</offsets></italic><offsets xml_i="26712" xml_f="26783" txt_i="14853" txt_f="14921"> &lt; 0.01) at the end of the study. However, in the CCP group, 25(OH)D</offsets><sub><offsets xml_i="26788" xml_f="26789" txt_i="14921" txt_f="14922">3</offsets></sub><offsets xml_i="26795" xml_f="26864" txt_i="14922" txt_f="14991"> levels did not change significantly (from 19.2 ± 7.4 to 23.4 ± 7.5 (</offsets><italic><offsets xml_i="26872" xml_f="26873" txt_i="14991" txt_f="14992">p</offsets></italic><offsets xml_i="26882" xml_f="26893" txt_i="14992" txt_f="15003"> = 0.46)) (</offsets><xref ref-type="table" rid="nutrients-10-00196-t002"><offsets xml_i="26946" xml_f="26953" txt_i="15003" txt_f="15010">Table 2</offsets></xref><offsets xml_i="26960" xml_f="27036" txt_i="15010" txt_f="15086">). A significant number of patients in the CCC group achieved target 25(OH)D</offsets><sub><offsets xml_i="27041" xml_f="27042" txt_i="15086" txt_f="15087">3</offsets></sub><offsets xml_i="27048" xml_f="27147" txt_i="15087" txt_f="15186"> level (≥30 ng/dL) as early as the 12th week compared to the CCP group (21/27 (78%) vs. 2/28 (7%), </offsets><italic><offsets xml_i="27155" xml_f="27156" txt_i="15186" txt_f="15187">p</offsets></italic><offsets xml_i="27165" xml_f="27319" txt_i="15187" txt_f="15341"> = 0.001 at 12th week); and nearly 89% of the CCC group vs only 10.7% in the CCP group achieved the target level at the end of the study (24/27 vs. 3/28, </offsets><italic><offsets xml_i="27327" xml_f="27328" txt_i="15341" txt_f="15342">p</offsets></italic><offsets xml_i="27337" xml_f="27366" txt_i="15342" txt_f="15371"> = 0.001 (chi-square test)) (</offsets><xref ref-type="table" rid="nutrients-10-00196-t006"><offsets xml_i="27419" xml_f="27426" txt_i="15371" txt_f="15378">Table 6</offsets></xref><offsets xml_i="27433" xml_f="27435" txt_i="15378" txt_f="15380">).</offsets></p></sec><sec id="sec3dot4-nutrients-10-00196"><title><offsets xml_i="27490" xml_f="27560" txt_i="15382" txt_f="15452">3.4. Changes in Serum Bone Turnover Markers and Bone Mineral Densities</offsets></title><p><offsets xml_i="27571" xml_f="27654" txt_i="15453" txt_f="15536">Serum BAP and TRACP-5b levels were not significantly different between the groups (</offsets><xref ref-type="table" rid="nutrients-10-00196-t002"><offsets xml_i="27707" xml_f="27714" txt_i="15536" txt_f="15543">Table 2</offsets></xref><offsets xml_i="27721" xml_f="27889" txt_i="15543" txt_f="15711">). No obvious changes in serum Alk-P, cCa and P were noted. Although no significant differences in femoral neck and lumbar spine BMD were noted between the two groups (</offsets><xref ref-type="table" rid="nutrients-10-00196-t007"><offsets xml_i="27942" xml_f="27949" txt_i="15711" txt_f="15718">Table 7</offsets></xref><offsets xml_i="27956" xml_f="28114" txt_i="15718" txt_f="15876">), the number of patients who had 10% increase in FN BMD was insignificantly higher in the CCC group ((13/27) 40%) compared with the CCP group ((5/28) 6.7%) (</offsets><xref ref-type="table" rid="nutrients-10-00196-t006"><offsets xml_i="28167" xml_f="28174" txt_i="15876" txt_f="15883">Table 6</offsets></xref><offsets xml_i="28181" xml_f="28183" txt_i="15883" txt_f="15885">).</offsets></p></sec></sec><sec id="sec4-nutrients-10-00196"><title><offsets xml_i="28240" xml_f="28253" txt_i="15888" txt_f="15901">4. Discussion</offsets></title><p><offsets xml_i="28264" xml_f="28488" txt_i="15902" txt_f="16126">Our results demonstrated that more than 80% of patients with severe SHPT achieved the primary target serum iPTH ≤300 pg/ml level with cholecalciferol supplementation. Nearly 90% of patients achieved the target serum 25-(OH)D</offsets><sub><offsets xml_i="28493" xml_f="28494" txt_i="16126" txt_f="16127">3</offsets></sub><offsets xml_i="28500" xml_f="28918" txt_i="16127" txt_f="16545"> (≥30 ng/mL) with high-dose cholecalciferol supplementation (5000 IU/day). About 40% of patients receiving cholecalciferol achieved a 10% increase in FN BMD by the end of the study. To our knowledge, this is the first study to reveal the beneficial effects of cholecalciferol supplementation in further lowering iPTH and bone density improvement when combined with cinacalcet and calcitriol among severe SHPT patients.</offsets></p><p><offsets xml_i="28925" xml_f="29072" txt_i="16546" txt_f="16693">As previously described, cinacalcet significantly increases the oxyphil cells (OC) and chief cells (CC) OC/CC ratio (approx. increase 3.42 times) [</offsets><xref rid="B24-nutrients-10-00196" ref-type="bibr"><offsets xml_i="29123" xml_f="29125" txt_i="16693" txt_f="16695">24</offsets></xref><offsets xml_i="29132" xml_f="29182" txt_i="16695" txt_f="16745">], further increases local calcitriol production [</offsets><xref rid="B26-nutrients-10-00196" ref-type="bibr"><offsets xml_i="29233" xml_f="29235" txt_i="16745" txt_f="16747">26</offsets></xref><offsets xml_i="29242" xml_f="29344" txt_i="16747" txt_f="16849">], and regulates local PTH secretion in a paracrine/autocrine manner. Thus, the need for local 25(OH)D</offsets><sub><offsets xml_i="29349" xml_f="29350" txt_i="16849" txt_f="16850">3</offsets></sub><offsets xml_i="29356" xml_f="29504" txt_i="16850" txt_f="16998"> substrate increases with cinacalcet treatment. We proved in our study that addition of nutritional vitamin D (cholecalciferol) improves the 25(OH)D</offsets><sub><offsets xml_i="29509" xml_f="29510" txt_i="16998" txt_f="16999">3</offsets></sub><offsets xml_i="29516" xml_f="29987" txt_i="16999" txt_f="17470"> requirement by cinacalcet treatment, and further inhibits PTH secretion among those patients with severe SHPT when used in combination with cinacalcet/active vitamin D analogs. About 55% of the patients achieved the iPTH target (iPTH ≤ 300 pg/mL) at the 20th week and almost 81% of patients achieved that target after the 24th week of cholecalciferol supplementation. This effect was also seen among those patients with severely deficient vitamin D levels (serum 25(OH)D</offsets><sub><offsets xml_i="29992" xml_f="29993" txt_i="17470" txt_f="17471">3</offsets></sub><offsets xml_i="29999" xml_f="30173" txt_i="17471" txt_f="17642"> &lt; 12.5 ng/mL). Furthermore, a higher percentage of patients achieved the primary endpoint in the CCC group, irrespective of the prior use of active vitamin D, calcitriol.</offsets></p><p><offsets xml_i="30180" xml_f="30477" txt_i="17643" txt_f="17940">Although the CCP group also significantly improved iPTH levels, the target iPTH level was not achieved in most patients by the end of the study. Previous studies also proved that cinacalcet therapy improved the targets of bone metabolism (PTH, Ca, P, and the Ca-P product (Ca-P)) when used alone [</offsets><xref rid="B32-nutrients-10-00196" ref-type="bibr"><offsets xml_i="30528" xml_f="30530" txt_i="17940" txt_f="17942">32</offsets></xref><offsets xml_i="30537" xml_f="30595" txt_i="17942" txt_f="18000">] or in combination of low-dose active vitamin D analogs [</offsets><xref rid="B7-nutrients-10-00196" ref-type="bibr"><offsets xml_i="30645" xml_f="30646" txt_i="18000" txt_f="18001">7</offsets></xref><offsets xml_i="30653" xml_f="31046" txt_i="18001" txt_f="18394">]. However, all these studies used titrated doses of cinacalcet (30–180 mg per day) according to biochemical measures. We used a single daily dose of cinacalcet (30 mg per day) throughout our study, since the drug is not covered by health insurance in Taiwan and patients took the drug by self-payment. We also found that lower doses of calcitriol were needed among our study group with time (</offsets><xref ref-type="table" rid="nutrients-10-00196-t005"><offsets xml_i="31099" xml_f="31106" txt_i="18394" txt_f="18401">Table 5</offsets></xref><offsets xml_i="31113" xml_f="31171" txt_i="18401" txt_f="18459">). Most of the CCC group patients achieved KDOQI targets [</offsets><xref rid="B33-nutrients-10-00196" ref-type="bibr"><offsets xml_i="31222" xml_f="31224" txt_i="18459" txt_f="18461">33</offsets></xref><offsets xml_i="31231" xml_f="31317" txt_i="18461" txt_f="18544">] (serum PTH 150–300 pg/mL, Ca 8.4–9.5 mg/dL, P 3.5–5.5 mg/dL, CaxP product &lt; 55 mg</offsets><sup><offsets xml_i="31322" xml_f="31323" txt_i="18544" txt_f="18545">2</offsets></sup><offsets xml_i="31329" xml_f="31332" txt_i="18545" txt_f="18548">/dL</offsets><sup><offsets xml_i="31337" xml_f="31338" txt_i="18548" txt_f="18549">2</offsets></sup><offsets xml_i="31344" xml_f="31633" txt_i="18549" txt_f="18838">) and none had hypocalcemia. Since hypocalcemia is the major event prohibiting the use of cinacalcet, and hypercalcemia is a major complication of active vitamin D analogs, the supplementation of nutritional vitamin D avoids both hypo- and hypercalcemic events in such combination therapy.</offsets></p><p><offsets xml_i="31640" xml_f="31707" txt_i="18839" txt_f="18906">We found that up to 70% of CCC patients achieved the target 25(OH)D</offsets><sub><offsets xml_i="31712" xml_f="31713" txt_i="18906" txt_f="18907">3</offsets></sub><offsets xml_i="31719" xml_f="32007" txt_i="18907" txt_f="19195"> level (≥30 ng/mL) from the 12th week of supplementation and nearly 90% had the target level by the end of the study. However, no such improvement was seen in the CCP group. Clinical studies reported that the combined use of nutritional vitamin D might reduce the active vitamin D doses [</offsets><xref rid="B3-nutrients-10-00196" ref-type="bibr"><offsets xml_i="32057" xml_f="32058" txt_i="19195" txt_f="19196">3</offsets></xref><offsets xml_i="32065" xml_f="32066" txt_i="19196" txt_f="19197">,</offsets><xref rid="B34-nutrients-10-00196" ref-type="bibr"><offsets xml_i="32117" xml_f="32119" txt_i="19197" txt_f="19199">34</offsets></xref><offsets xml_i="32126" xml_f="32367" txt_i="19199" txt_f="19440">] and improve adverse effects. Accordingly, we found our CCC group patients used progressively lower doses of calcitriol compared to the CCP group. Studies regarding the effective dosage of vitamin D supplementation are still controversial [</offsets><xref rid="B35-nutrients-10-00196" ref-type="bibr"><offsets xml_i="32418" xml_f="32420" txt_i="19440" txt_f="19442">35</offsets></xref><offsets xml_i="32427" xml_f="32428" txt_i="19442" txt_f="19443">,</offsets><xref rid="B36-nutrients-10-00196" ref-type="bibr"><offsets xml_i="32479" xml_f="32481" txt_i="19443" txt_f="19445">36</offsets></xref><offsets xml_i="32488" xml_f="32608" txt_i="19445" txt_f="19565">]. Our previous study used low-dose cholecalciferol (5000 IU/week) and about 60% of patients achieved the target 25(OH)D</offsets><sub><offsets xml_i="32613" xml_f="32614" txt_i="19565" txt_f="19566">3</offsets></sub><offsets xml_i="32620" xml_f="32652" txt_i="19566" txt_f="19598"> level (≥30 ng/dL) at 16 weeks [</offsets><xref rid="B10-nutrients-10-00196" ref-type="bibr"><offsets xml_i="32703" xml_f="32705" txt_i="19598" txt_f="19600">10</offsets></xref><offsets xml_i="32712" xml_f="32789" txt_i="19600" txt_f="19677">]. Growing evidence shows that active vitamin D analogs may aggravate 25(OH)D</offsets><sub><offsets xml_i="32794" xml_f="32795" txt_i="19677" txt_f="19678">3</offsets></sub><offsets xml_i="32801" xml_f="32883" txt_i="19678" txt_f="19760"> deficiency because of the feedback inhibition of hepatic 1α-OHase and 25α-OHase [</offsets><xref rid="B37-nutrients-10-00196" ref-type="bibr"><offsets xml_i="32934" xml_f="32936" txt_i="19760" txt_f="19762">37</offsets></xref><offsets xml_i="32943" xml_f="32944" txt_i="19762" txt_f="19763">,</offsets><xref rid="B38-nutrients-10-00196" ref-type="bibr"><offsets xml_i="32995" xml_f="32997" txt_i="19763" txt_f="19765">38</offsets></xref><offsets xml_i="33004" xml_f="33044" txt_i="19765" txt_f="19805">] and induction of the 24-OHase enzyme [</offsets><xref rid="B39-nutrients-10-00196" ref-type="bibr"><offsets xml_i="33095" xml_f="33097" txt_i="19805" txt_f="19807">39</offsets></xref><offsets xml_i="33104" xml_f="33245" txt_i="19807" txt_f="19948">]. Thus, we used quite a high dose of cholecalciferol (5000 IU/day) in combination with calcitriol in our study. We closely monitored 25(OH)D</offsets><sub><offsets xml_i="33250" xml_f="33251" txt_i="19948" txt_f="19949">3</offsets></sub><offsets xml_i="33257" xml_f="33378" txt_i="19949" txt_f="20070"> levels to avoid toxicity, and all of our patients tolerate high-dose cholecalciferol supplementation (5000 IU/day) well.</offsets></p><p><offsets xml_i="33385" xml_f="33703" txt_i="20071" txt_f="20386">The next major observation of our study was that about 40% in the CCC group gained &gt;10% improvement in femoral BMD compared with the CCP group (~7%). Other clinical studies also revealed that calcimimetic agents reduced the elevated bone formation rate/tissue area with improvement in high turnover bone disorders [</offsets><xref rid="B40-nutrients-10-00196" ref-type="bibr"><offsets xml_i="33754" xml_f="33756" txt_i="20386" txt_f="20388">40</offsets></xref><offsets xml_i="33763" xml_f="33764" txt_i="20388" txt_f="20389">,</offsets><xref rid="B41-nutrients-10-00196" ref-type="bibr"><offsets xml_i="33815" xml_f="33817" txt_i="20389" txt_f="20391">41</offsets></xref><offsets xml_i="33824" xml_f="34099" txt_i="20391" txt_f="20666">]. In a recent Indian study among CKD patients, researchers found a significant reduction in iPTH and bone turnover markers, bone-specific alkaline phosphatase (BAP) and serum C-terminal cross-linked collagen type I telopeptides (CTX-1) with cholecalciferol supplementation [</offsets><xref rid="B42-nutrients-10-00196" ref-type="bibr"><offsets xml_i="34150" xml_f="34152" txt_i="20666" txt_f="20668">42</offsets></xref><offsets xml_i="34159" xml_f="34180" txt_i="20668" txt_f="20689">]. Previous studies [</offsets><xref rid="B43-nutrients-10-00196" ref-type="bibr"><offsets xml_i="34231" xml_f="34233" txt_i="20689" txt_f="20691">43</offsets></xref><offsets xml_i="34240" xml_f="34241" txt_i="20691" txt_f="20692">,</offsets><xref rid="B44-nutrients-10-00196" ref-type="bibr"><offsets xml_i="34292" xml_f="34294" txt_i="20692" txt_f="20694">44</offsets></xref><offsets xml_i="34301" xml_f="34522" txt_i="20694" txt_f="20915">] also proved that cinacalcet treatment improves the BMD of the FN without affecting the LS BMD. How and whether the combination of these agents interacts to improve bone parameters needs to be explored in future studies.</offsets></p><p><offsets xml_i="34529" xml_f="35430" txt_i="20916" txt_f="21817">Our study has several limitations. Firstly, we cannot apply our findings or draw definitive conclusions in the general HD population due to the relatively small sample size; however, the results were indeed promising and clinically important. We used fixed low doses of cinacalcet in both study and control arms, which needed to be followed longer for efficiency. Furthermore, we excluded patients with severe malnutrition and inflammatory or infectious disorders who might have benefited the most from the intervention due to vitamin D deficiency. However, our cohort had significantly low vitamin D levels in both arms of the study. Next, we did not determine the morbidity or mortality benefits of combination therapy. Although we performed some questionnaires on various bone fractures, the results were inconsistent and non-significant due to shorter follow-up duration. The optimal serum 25(OH)D</offsets><sub><offsets xml_i="35435" xml_f="35436" txt_i="21817" txt_f="21818">3</offsets></sub><offsets xml_i="35442" xml_f="35562" txt_i="21818" txt_f="21938"> target level in dialysis patients remains unknown; however, we supposed some additive PTH lowering effects with 25(OH)D</offsets><sub><offsets xml_i="35567" xml_f="35568" txt_i="21938" txt_f="21939">3</offsets></sub><offsets xml_i="35574" xml_f="35848" txt_i="21939" txt_f="22213"> ≥ 30 ng/dL. Although no toxicity levels and signs were noted in our patients, the beneficial role and possible side effects of high-dose cholecalciferol in dialysis patients still requires a multifaceted long-term approach and needs further study in larger clinical trials.</offsets></p></sec><sec id="sec5-nutrients-10-00196"><title><offsets xml_i="35899" xml_f="35913" txt_i="22215" txt_f="22229">5. Conclusions</offsets></title><p><offsets xml_i="35924" xml_f="35974" txt_i="22230" txt_f="22280">Our findings provide in vivo evidence that 25(OH)D</offsets><sub><offsets xml_i="35979" xml_f="35980" txt_i="22280" txt_f="22281">3</offsets></sub><offsets xml_i="35986" xml_f="36365" txt_i="22281" txt_f="22660"> repletion with high-dose cholecalciferol acts additively with low-dose cinacalcet and active vitamin D analogs to gain K/DOQI targets of bone metabolism markers and improve femoral neck bone mineral density in dialysis patients. We recommend that the addition of cholecalciferol is more favorable than the titration of cinacalcet and calcitriol doses among severe SHPT patients.</offsets></p></sec></body><back><ack><title>Acknowledgments</title><p>We acknowledge the commitment and dedication of the study investigators at Cardinal Tien Hospital, Fu Jen Catholic University and Shuang Ho Hospital, Taipei Medical University. The clinical trial was funded by CTH 105A-215, CTH-106A-2B01, 103TMU-SHH-28, CTH-100-1-2A0 and NC10003 for data collection, analysis, and preparation of the study report and manuscript.</p></ack><notes><title>Author Contributions</title><p>Kuo-Cheng Lu, Yuh-Feng Lin and Yung-Ho Hsu conceived and designed the trial; Chia-Chao Wu, Chi-Feng Hung, Min-Tser Liao and Jia-Fwu Shyu performed the trial; Chien-Lin Lu, Yuan-Hung Wang and Tian-Jong Chang analyzed the data; Cai-Mei Zheng wrote the paper. All authors read and approved the final manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interests.</p></notes><ref-list><title>References</title><ref id="B1-nutrients-10-00196"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foley</surname><given-names>R.N.</given-names></name><name><surname>Parfrey</surname><given-names>P.S.</given-names></name><name><surname>Sarnak</surname><given-names>M.J.</given-names></name></person-group><article-title>Clinical epidemiology of cardiovascular disease in chronic renal disease</article-title><source>Am. J. Kidney Dis. Off. J. Natl. Kidney Found.</source><year>1998</year><volume>32</volume><fpage>S112</fpage><lpage>S119</lpage><pub-id pub-id-type="doi">10.1053/ajkd.1998.v32.pm9820470</pub-id></element-citation></ref><ref id="B2-nutrients-10-00196"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massry</surname><given-names>S.G.</given-names></name><name><surname>Smogorzewski</surname><given-names>M.</given-names></name></person-group><article-title>Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia</article-title><source>Semin. Nephrol.</source><year>1994</year><volume>14</volume><fpage>219</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">8036356</pub-id></element-citation></ref><ref id="B3-nutrients-10-00196"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briese</surname><given-names>S.</given-names></name><name><surname>Wiesner</surname><given-names>S.</given-names></name><name><surname>Will</surname><given-names>J.C.</given-names></name><name><surname>Lembcke</surname><given-names>A.</given-names></name><name><surname>Opgen-Rhein</surname><given-names>B.</given-names></name><name><surname>Nissel</surname><given-names>R.</given-names></name><name><surname>Wernecke</surname><given-names>K.D.</given-names></name><name><surname>Andreae</surname><given-names>J.</given-names></name><name><surname>Haffner</surname><given-names>D.</given-names></name><name><surname>Querfeld</surname><given-names>U.</given-names></name></person-group><article-title>Arterial and cardiac disease in young adults with childhood-onset end-stage renal disease-impact of calcium and vitamin D therapy</article-title><source>Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc.</source><year>2006</year><volume>21</volume><fpage>1906</fpage><lpage>1914</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfl098</pub-id><pub-id pub-id-type="pmid">16554325</pub-id></element-citation></ref><ref id="B4-nutrients-10-00196"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lomashvili</surname><given-names>K.A.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>O’Neill</surname><given-names>W.C.</given-names></name></person-group><article-title>Role of local versus systemic vitamin D receptors in vascular calcification</article-title><source>Arterioscler. Thromb. Vasc. Biol.</source><year>2014</year><volume>34</volume><fpage>146</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.113.302525</pub-id><pub-id pub-id-type="pmid">24202304</pub-id></element-citation></ref><ref id="B5-nutrients-10-00196"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chertow</surname><given-names>G.M.</given-names></name><name><surname>Blumenthal</surname><given-names>S.</given-names></name><name><surname>Turner</surname><given-names>S.</given-names></name><name><surname>Roppolo</surname><given-names>M.</given-names></name><name><surname>Stern</surname><given-names>L.</given-names></name><name><surname>Chi</surname><given-names>E.M.</given-names></name><name><surname>Reed</surname><given-names>J.</given-names></name><name><surname>Investigators</surname><given-names>C.</given-names></name></person-group><article-title>Cinacalcet hydrochloride (sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate</article-title><source>Clin. J. Am. Soc. Nephrol. CJASN</source><year>2006</year><volume>1</volume><fpage>305</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.2215/CJN.00870805</pub-id><pub-id pub-id-type="pmid">17699221</pub-id></element-citation></ref><ref id="B6-nutrients-10-00196"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Block</surname><given-names>G.A.</given-names></name><name><surname>Zeig</surname><given-names>S.</given-names></name><name><surname>Sugihara</surname><given-names>J.</given-names></name><name><surname>Chertow</surname><given-names>G.M.</given-names></name><name><surname>Chi</surname><given-names>E.M.</given-names></name><name><surname>Turner</surname><given-names>S.A.</given-names></name><name><surname>Bushinsky</surname><given-names>D.A.</given-names></name><name><surname>Investigators</surname><given-names>T.</given-names></name></person-group><article-title>Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism</article-title><source>Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc.</source><year>2008</year><volume>23</volume><fpage>2311</fpage><lpage>2318</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfn026</pub-id><pub-id pub-id-type="pmid">18310602</pub-id></element-citation></ref><ref id="B7-nutrients-10-00196"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fishbane</surname><given-names>S.</given-names></name><name><surname>Shapiro</surname><given-names>W.B.</given-names></name><name><surname>Corry</surname><given-names>D.B.</given-names></name><name><surname>Vicks</surname><given-names>S.L.</given-names></name><name><surname>Roppolo</surname><given-names>M.</given-names></name><name><surname>Rappaport</surname><given-names>K.</given-names></name><name><surname>Ling</surname><given-names>X.</given-names></name><name><surname>Goodman</surname><given-names>W.G.</given-names></name><name><surname>Turner</surname><given-names>S.</given-names></name><name><surname>Charytan</surname><given-names>C.</given-names></name></person-group><article-title>Cinacalcet hcl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: The achieve study results</article-title><source>Clin. J. Am. Soc. Nephrol. CJASN</source><year>2008</year><volume>3</volume><fpage>1718</fpage><lpage>1725</lpage><pub-id pub-id-type="doi">10.2215/CJN.01040308</pub-id><pub-id pub-id-type="pmid">18945995</pub-id></element-citation></ref><ref id="B8-nutrients-10-00196"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Messa</surname><given-names>P.</given-names></name><name><surname>Macario</surname><given-names>F.</given-names></name><name><surname>Yaqoob</surname><given-names>M.</given-names></name><name><surname>Bouman</surname><given-names>K.</given-names></name><name><surname>Braun</surname><given-names>J.</given-names></name><name><surname>von Albertini</surname><given-names>B.</given-names></name><name><surname>Brink</surname><given-names>H.</given-names></name><name><surname>Maduell</surname><given-names>F.</given-names></name><name><surname>Graf</surname><given-names>H.</given-names></name><name><surname>Frazao</surname><given-names>J.M.</given-names></name><etal></etal></person-group><article-title>The optima study: Assessing a new cinacalcet (sensipar/mimpara) treatment algorithm for secondary hyperparathyroidism</article-title><source>Clin. J. Am. Soc. Nephrol. CJASN</source><year>2008</year><volume>3</volume><fpage>36</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.2215/CJN.03591006</pub-id><pub-id pub-id-type="pmid">18178780</pub-id></element-citation></ref><ref id="B9-nutrients-10-00196"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Block</surname><given-names>G.A.</given-names></name><name><surname>Martin</surname><given-names>K.J.</given-names></name><name><surname>de Francisco</surname><given-names>A.L.</given-names></name><name><surname>Turner</surname><given-names>S.A.</given-names></name><name><surname>Avram</surname><given-names>M.M.</given-names></name><name><surname>Suranyi</surname><given-names>M.G.</given-names></name><name><surname>Hercz</surname><given-names>G.</given-names></name><name><surname>Cunningham</surname><given-names>J.</given-names></name><name><surname>Abu-Alfa</surname><given-names>A.K.</given-names></name><name><surname>Messa</surname><given-names>P.</given-names></name><etal></etal></person-group><article-title>Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis</article-title><source>N. Engl. J. Med.</source><year>2004</year><volume>350</volume><fpage>1516</fpage><lpage>1525</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa031633</pub-id><pub-id pub-id-type="pmid">15071126</pub-id></element-citation></ref><ref id="B10-nutrients-10-00196"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>J.Q.</given-names></name><name><surname>Hou</surname><given-names>Y.C.</given-names></name><name><surname>Zheng</surname><given-names>C.M.</given-names></name><name><surname>Lu</surname><given-names>C.L.</given-names></name><name><surname>Liu</surname><given-names>W.C.</given-names></name><name><surname>Wu</surname><given-names>C.C.</given-names></name><name><surname>Huang</surname><given-names>M.T.</given-names></name><name><surname>Lin</surname><given-names>Y.F.</given-names></name><name><surname>Lu</surname><given-names>K.C.</given-names></name></person-group><article-title>Cholecalciferol additively reduces serum parathyroid hormone and increases vitamin D and cathelicidin levels in paricalcitol-treated secondary hyperparathyroid hemodialysis patients</article-title><source>Nutrients</source><year>2016</year><volume>8</volume><elocation-id>708</elocation-id><pub-id pub-id-type="doi">10.3390/nu8110708</pub-id><pub-id pub-id-type="pmid">27827962</pub-id></element-citation></ref><ref id="B11-nutrients-10-00196"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harkness</surname><given-names>L.</given-names></name><name><surname>Cromer</surname><given-names>B.</given-names></name></person-group><article-title>Low levels of 25-hydroxy vitamin D are associated with elevated parathyroid hormone in healthy adolescent females</article-title><source>Osteoporos. Int.</source><year>2005</year><volume>16</volume><fpage>109</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1007/s00198-004-1656-8</pub-id><pub-id pub-id-type="pmid">15175848</pub-id></element-citation></ref><ref id="B12-nutrients-10-00196"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vieth</surname><given-names>R.</given-names></name><name><surname>Ladak</surname><given-names>Y.</given-names></name><name><surname>Walfish</surname><given-names>P.G.</given-names></name></person-group><article-title>Age-related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D</article-title><source>J. Clin. Endocrinol. Metab.</source><year>2003</year><volume>88</volume><fpage>185</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1210/jc.2002-021064</pub-id><pub-id pub-id-type="pmid">12519850</pub-id></element-citation></ref><ref id="B13-nutrients-10-00196"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dusso</surname><given-names>A.</given-names></name><name><surname>Brown</surname><given-names>A.</given-names></name><name><surname>Slatopolsky</surname><given-names>E.</given-names></name></person-group><article-title>Extrarenal production of calcitriol</article-title><source>Semin. Nephrol.</source><year>1994</year><volume>14</volume><fpage>144</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">8177981</pub-id></element-citation></ref><ref id="B14-nutrients-10-00196"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zehnder</surname><given-names>D.</given-names></name><name><surname>Bland</surname><given-names>R.</given-names></name><name><surname>Williams</surname><given-names>M.C.</given-names></name><name><surname>McNinch</surname><given-names>R.W.</given-names></name><name><surname>Howie</surname><given-names>A.J.</given-names></name><name><surname>Stewart</surname><given-names>P.M.</given-names></name><name><surname>Hewison</surname><given-names>M.</given-names></name></person-group><article-title>Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase</article-title><source>J. Clin. Endocrinol. Metab.</source><year>2001</year><volume>86</volume><fpage>888</fpage><lpage>894</lpage><pub-id pub-id-type="pmid">11158062</pub-id></element-citation></ref><ref id="B15-nutrients-10-00196"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levin</surname><given-names>A.</given-names></name><name><surname>Bakris</surname><given-names>G.L.</given-names></name><name><surname>Molitch</surname><given-names>M.</given-names></name><name><surname>Smulders</surname><given-names>M.</given-names></name><name><surname>Tian</surname><given-names>J.</given-names></name><name><surname>Williams</surname><given-names>L.A.</given-names></name><name><surname>Andress</surname><given-names>D.L.</given-names></name></person-group><article-title>Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease</article-title><source>Kidney Int.</source><year>2007</year><volume>71</volume><fpage>31</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1038/sj.ki.5002009</pub-id><pub-id pub-id-type="pmid">17091124</pub-id></element-citation></ref><ref id="B16-nutrients-10-00196"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>H.Y.</given-names></name><name><surname>Hyun</surname><given-names>H.S.</given-names></name><name><surname>Kang</surname><given-names>H.G.</given-names></name><name><surname>Ha</surname><given-names>I.S.</given-names></name><name><surname>Cheong</surname><given-names>H.I.</given-names></name></person-group><article-title>Prevalence of 25(oh) vitamin D insufficiency and deficiency in pediatric patients on chronic dialysis</article-title><source>Perit. Dial. Int.</source><year>2013</year><volume>33</volume><fpage>398</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.3747/pdi.2011.00246</pub-id><pub-id pub-id-type="pmid">23209039</pub-id></element-citation></ref><ref id="B17-nutrients-10-00196"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Segersten</surname><given-names>U.</given-names></name><name><surname>Correa</surname><given-names>P.</given-names></name><name><surname>Hewison</surname><given-names>M.</given-names></name><name><surname>Hellman</surname><given-names>P.</given-names></name><name><surname>Dralle</surname><given-names>H.</given-names></name><name><surname>Carling</surname><given-names>T.</given-names></name><name><surname>Akerstrom</surname><given-names>G.</given-names></name><name><surname>Westin</surname><given-names>G.</given-names></name></person-group><article-title>25-hydroxyvitamin d(3)-1alpha-hydroxylase expression in normal and pathological parathyroid glands</article-title><source>J. Clin. Endocrinol. Metab.</source><year>2002</year><volume>87</volume><fpage>2967</fpage><lpage>2972</lpage><pub-id pub-id-type="pmid">12050281</pub-id></element-citation></ref><ref id="B18-nutrients-10-00196"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Correa</surname><given-names>P.</given-names></name><name><surname>Segersten</surname><given-names>U.</given-names></name><name><surname>Hellman</surname><given-names>P.</given-names></name><name><surname>Akerstrom</surname><given-names>G.</given-names></name><name><surname>Westin</surname><given-names>G.</given-names></name></person-group><article-title>Increased 25-hydroxyvitamin d3 1alpha-hydroxylase and reduced 25-hydroxyvitamin d3 24-hydroxylase expression in parathyroid tumors—New prospects for treatment of hyperparathyroidism with vitamin D</article-title><source>J. Clin. Endocrinol. Metab.</source><year>2002</year><volume>87</volume><fpage>5826</fpage><lpage>5829</lpage><pub-id pub-id-type="doi">10.1210/jc.2002-021356</pub-id><pub-id pub-id-type="pmid">12466393</pub-id></element-citation></ref><ref id="B19-nutrients-10-00196"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritter</surname><given-names>C.S.</given-names></name><name><surname>Armbrecht</surname><given-names>H.J.</given-names></name><name><surname>Slatopolsky</surname><given-names>E.</given-names></name><name><surname>Brown</surname><given-names>A.J.</given-names></name></person-group><article-title>25-hydroxyvitamin d(3) suppresses PTH synthesis and secretion by bovine parathyroid cells</article-title><source>Kidney Int.</source><year>2006</year><volume>70</volume><fpage>654</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1038/sj.ki.5000394</pub-id><pub-id pub-id-type="pmid">16807549</pub-id></element-citation></ref><ref id="B20-nutrients-10-00196"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christie</surname><given-names>A.C.</given-names></name></person-group><article-title>The parathyroid oxyphil cells</article-title><source>J. Clin. Pathol.</source><year>1967</year><volume>20</volume><fpage>591</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1136/jcp.20.4.591</pub-id><pub-id pub-id-type="pmid">4880406</pub-id></element-citation></ref><ref id="B21-nutrients-10-00196"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lomonte</surname><given-names>C.</given-names></name><name><surname>Martino</surname><given-names>R.</given-names></name><name><surname>Selvaggiolo</surname><given-names>M.</given-names></name><name><surname>Bona</surname><given-names>R.M.</given-names></name><name><surname>Cazzato</surname><given-names>F.</given-names></name><name><surname>Milano</surname><given-names>R.</given-names></name><name><surname>Chiarulli</surname><given-names>G.</given-names></name><name><surname>Basile</surname><given-names>C.</given-names></name></person-group><article-title>Calcitriol pulse therapy and histology of parathyroid glands in hemodialysis patients</article-title><source>J. Nephrol.</source><year>2003</year><volume>16</volume><fpage>716</fpage><lpage>720</lpage><pub-id pub-id-type="pmid">14733419</pub-id></element-citation></ref><ref id="B22-nutrients-10-00196"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizobuchi</surname><given-names>M.</given-names></name><name><surname>Ogata</surname><given-names>H.</given-names></name><name><surname>Hatamura</surname><given-names>I.</given-names></name><name><surname>Saji</surname><given-names>F.</given-names></name><name><surname>Koiwa</surname><given-names>F.</given-names></name><name><surname>Kinugasa</surname><given-names>E.</given-names></name><name><surname>Koshikawa</surname><given-names>S.</given-names></name><name><surname>Akizawa</surname><given-names>T.</given-names></name></person-group><article-title>Activation of calcium-sensing receptor accelerates apoptosis in hyperplastic parathyroid cells</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2007</year><volume>362</volume><fpage>11</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2007.07.177</pub-id><pub-id pub-id-type="pmid">17706605</pub-id></element-citation></ref><ref id="B23-nutrients-10-00196"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drueke</surname><given-names>T.</given-names></name><name><surname>Martin</surname><given-names>D.</given-names></name><name><surname>Rodriguez</surname><given-names>M.</given-names></name></person-group><article-title>Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies</article-title><source>Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc.</source><year>2007</year><volume>22</volume><fpage>1828</fpage><lpage>1839</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfm177</pub-id><pub-id pub-id-type="pmid">17449493</pub-id></element-citation></ref><ref id="B24-nutrients-10-00196"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lomonte</surname><given-names>C.</given-names></name><name><surname>Vernaglione</surname><given-names>L.</given-names></name><name><surname>Chimienti</surname><given-names>D.</given-names></name><name><surname>Bruno</surname><given-names>A.</given-names></name><name><surname>Cocola</surname><given-names>S.</given-names></name><name><surname>Teutonico</surname><given-names>A.</given-names></name><name><surname>Cazzato</surname><given-names>F.</given-names></name><name><surname>Basile</surname><given-names>C.</given-names></name></person-group><article-title>Does vitamin D receptor and calcium receptor activation therapy play a role in the histopathologic alterations of parathyroid glands in refractory uremic hyperparathyroidism?</article-title><source>Clin. J. Am. Soc. Nephrol. CJASN</source><year>2008</year><volume>3</volume><fpage>794</fpage><lpage>799</lpage><pub-id pub-id-type="doi">10.2215/CJN.04150907</pub-id><pub-id pub-id-type="pmid">18322048</pub-id></element-citation></ref><ref id="B25-nutrients-10-00196"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sumida</surname><given-names>K.</given-names></name><name><surname>Nakamura</surname><given-names>M.</given-names></name><name><surname>Ubara</surname><given-names>Y.</given-names></name><name><surname>Marui</surname><given-names>Y.</given-names></name><name><surname>Tanaka</surname><given-names>K.</given-names></name><name><surname>Takaichi</surname><given-names>K.</given-names></name><name><surname>Tomikawa</surname><given-names>S.</given-names></name><name><surname>Inoshita</surname><given-names>N.</given-names></name><name><surname>Ohashi</surname><given-names>K.</given-names></name></person-group><article-title>Histopathological alterations of the parathyroid glands in haemodialysis patients with secondary hyperparathyroidism refractory to cinacalcet hydrochloride</article-title><source>J. Clin. Pathol.</source><year>2011</year><volume>64</volume><fpage>756</fpage><lpage>760</lpage><pub-id pub-id-type="doi">10.1136/jclinpath-2011-200100</pub-id><pub-id pub-id-type="pmid">21565858</pub-id></element-citation></ref><ref id="B26-nutrients-10-00196"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritter</surname><given-names>C.S.</given-names></name><name><surname>Haughey</surname><given-names>B.H.</given-names></name><name><surname>Armbrecht</surname><given-names>H.J.</given-names></name><name><surname>Brown</surname><given-names>A.J.</given-names></name></person-group><article-title>Distribution and regulation of the 25-hydroxyvitamin d3 1alpha-hydroxylase in human parathyroid glands</article-title><source>J. Steroid Biochem. Mol. Biol.</source><year>2012</year><volume>130</volume><fpage>73</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.jsbmb.2012.01.010</pub-id><pub-id pub-id-type="pmid">22326730</pub-id></element-citation></ref><ref id="B27-nutrients-10-00196"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendoza</surname><given-names>F.J.</given-names></name><name><surname>Lopez</surname><given-names>I.</given-names></name><name><surname>Canalejo</surname><given-names>R.</given-names></name><name><surname>Almaden</surname><given-names>Y.</given-names></name><name><surname>Martin</surname><given-names>D.</given-names></name><name><surname>Aguilera-Tejero</surname><given-names>E.</given-names></name><name><surname>Rodriguez</surname><given-names>M.</given-names></name></person-group><article-title>Direct upregulation of parathyroid calcium-sensing receptor and vitamin D receptor by calcimimetics in uremic rats</article-title><source>Am. J. Physiol. Ren. Physiol.</source><year>2009</year><volume>296</volume><fpage>F605</fpage><lpage>F613</lpage><pub-id pub-id-type="doi">10.1152/ajprenal.90272.2008</pub-id><pub-id pub-id-type="pmid">19091789</pub-id></element-citation></ref><ref id="B28-nutrients-10-00196"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizobuchi</surname><given-names>M.</given-names></name><name><surname>Hatamura</surname><given-names>I.</given-names></name><name><surname>Ogata</surname><given-names>H.</given-names></name><name><surname>Saji</surname><given-names>F.</given-names></name><name><surname>Uda</surname><given-names>S.</given-names></name><name><surname>Shiizaki</surname><given-names>K.</given-names></name><name><surname>Sakaguchi</surname><given-names>T.</given-names></name><name><surname>Negi</surname><given-names>S.</given-names></name><name><surname>Kinugasa</surname><given-names>E.</given-names></name><name><surname>Koshikawa</surname><given-names>S.</given-names></name><etal></etal></person-group><article-title>Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency</article-title><source>J. Am. Soc. Nephrol.</source><year>2004</year><volume>15</volume><fpage>2579</fpage><lpage>2587</lpage><pub-id pub-id-type="doi">10.1097/01.ASN.0000141016.20133.33</pub-id><pub-id pub-id-type="pmid">15466262</pub-id></element-citation></ref><ref id="B29-nutrients-10-00196"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faul</surname><given-names>F.</given-names></name><name><surname>Erdfelder</surname><given-names>E.</given-names></name><name><surname>Lang</surname><given-names>A.G.</given-names></name><name><surname>Buchner</surname><given-names>A.</given-names></name></person-group><article-title>G* power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences</article-title><source>Behav. Res. Methods</source><year></year><volume>39</volume><fpage>175</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.3758/BF03193146</pub-id><pub-id pub-id-type="pmid">17695343</pub-id></element-citation></ref><ref id="B30-nutrients-10-00196"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barreto</surname><given-names>F.C.</given-names></name><name><surname>Barreto</surname><given-names>D.V.</given-names></name><name><surname>Moyses</surname><given-names>R.M.</given-names></name><name><surname>Neves</surname><given-names>K.R.</given-names></name><name><surname>Canziani</surname><given-names>M.E.</given-names></name><name><surname>Draibe</surname><given-names>S.A.</given-names></name><name><surname>Jorgetti</surname><given-names>V.</given-names></name><name><surname>Carvalho</surname><given-names>A.B.</given-names></name></person-group><article-title>K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients</article-title><source>Kidney Int.</source><year>2008</year><volume>73</volume><fpage>771</fpage><lpage>777</lpage><pub-id pub-id-type="doi">10.1038/sj.ki.5002769</pub-id><pub-id pub-id-type="pmid">18185506</pub-id></element-citation></ref><ref id="B31-nutrients-10-00196"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kovacevic</surname><given-names>B.</given-names></name><name><surname>Ignjatovic</surname><given-names>M.</given-names></name><name><surname>Zivaljevic</surname><given-names>V.</given-names></name><name><surname>Cuk</surname><given-names>V.</given-names></name><name><surname>Scepanovic</surname><given-names>M.</given-names></name><name><surname>Petrovic</surname><given-names>Z.</given-names></name><name><surname>Paunovic</surname><given-names>I.</given-names></name></person-group><article-title>Parathyroidectomy for the attainment of NKF-K/DOQI and kdigo recommended values for bone and mineral metabolism in dialysis patients with uncontrollable secondary hyperparathyroidism</article-title><source>Langenbecks Arch. Surg.</source><year>2012</year><volume>397</volume><fpage>413</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1007/s00423-011-0901-9</pub-id><pub-id pub-id-type="pmid">22240976</pub-id></element-citation></ref><ref id="B32-nutrients-10-00196"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moe</surname><given-names>S.M.</given-names></name><name><surname>Chertow</surname><given-names>G.M.</given-names></name><name><surname>Coburn</surname><given-names>J.W.</given-names></name><name><surname>Quarles</surname><given-names>L.D.</given-names></name><name><surname>Goodman</surname><given-names>W.G.</given-names></name><name><surname>Block</surname><given-names>G.A.</given-names></name><name><surname>Drueke</surname><given-names>T.B.</given-names></name><name><surname>Cunningham</surname><given-names>J.</given-names></name><name><surname>Sherrard</surname><given-names>D.J.</given-names></name><name><surname>McCary</surname><given-names>L.C.</given-names></name><etal></etal></person-group><article-title>Achieving nkf-K/DOQI bone metabolism and disease treatment goals with cinacalcet hcl</article-title><source>Kidney Int.</source><year>2005</year><volume>67</volume><fpage>760</fpage><lpage>771</lpage><pub-id pub-id-type="doi">10.1111/j.1523-1755.2005.67139.x</pub-id><pub-id pub-id-type="pmid">15673327</pub-id></element-citation></ref><ref id="B33-nutrients-10-00196"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noordzij</surname><given-names>M.</given-names></name><name><surname>Korevaar</surname><given-names>J.C.</given-names></name><name><surname>Boeschoten</surname><given-names>E.W.</given-names></name><name><surname>Dekker</surname><given-names>F.W.</given-names></name><name><surname>Bos</surname><given-names>W.J.</given-names></name><name><surname>Krediet</surname><given-names>R.T.</given-names></name></person-group><article-title>Netherlands Cooperative Study on the Adequacy of Dialysis Study, G. The kidney disease outcomes quality initiative (K/DOQI) guideline for bone metabolism and disease in ckd: Association with mortality in dialysis patients</article-title><source>Am. J. Kidney Dis. Off. J. Natl. Kidney Found.</source><year>2005</year><volume>46</volume><fpage>925</fpage><lpage>932</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2005.08.013</pub-id><pub-id pub-id-type="pmid">16253734</pub-id></element-citation></ref><ref id="B34-nutrients-10-00196"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W.C.</given-names></name><name><surname>Wu</surname><given-names>C.C.</given-names></name><name><surname>Hung</surname><given-names>Y.M.</given-names></name><name><surname>Liao</surname><given-names>M.T.</given-names></name><name><surname>Shyu</surname><given-names>J.F.</given-names></name><name><surname>Lin</surname><given-names>Y.F.</given-names></name><name><surname>Lu</surname><given-names>K.C.</given-names></name><name><surname>Yeh</surname><given-names>K.C.</given-names></name></person-group><article-title>Pleiotropic effects of vitamin D in chronic kidney disease</article-title><source>Clin. Chim. Acta</source><year>2016</year><volume>453</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2015.11.029</pub-id><pub-id pub-id-type="pmid">26656443</pub-id></element-citation></ref><ref id="B35-nutrients-10-00196"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delanaye</surname><given-names>P.</given-names></name><name><surname>Weekers</surname><given-names>L.</given-names></name><name><surname>Warling</surname><given-names>X.</given-names></name><name><surname>Moonen</surname><given-names>M.</given-names></name><name><surname>Smelten</surname><given-names>N.</given-names></name><name><surname>Medart</surname><given-names>L.</given-names></name><name><surname>Krzesinski</surname><given-names>J.M.</given-names></name><name><surname>Cavalier</surname><given-names>E.</given-names></name></person-group><article-title>Cholecalciferol in haemodialysis patients: A randomized, double-blind, proof-of-concept and safety study</article-title><source>Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc.</source><year>2013</year><volume>28</volume><fpage>1779</fpage><lpage>1786</lpage><pub-id pub-id-type="doi">10.1093/ndt/gft001</pub-id><pub-id pub-id-type="pmid">23378417</pub-id></element-citation></ref><ref id="B36-nutrients-10-00196"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bansal</surname><given-names>B.</given-names></name><name><surname>Bansal</surname><given-names>S.B.</given-names></name><name><surname>Mithal</surname><given-names>A.</given-names></name><name><surname>Kher</surname><given-names>V.</given-names></name><name><surname>Marwaha</surname><given-names>R.</given-names></name><name><surname>Singh</surname><given-names>P.</given-names></name><name><surname>Irfan</surname><given-names>N.</given-names></name></person-group><article-title>A randomized controlled trial of cholecalciferol supplementation in patients on maintenance hemodialysis</article-title><source>Indian J. Endocrinol. Metab.</source><year>2014</year><volume>18</volume><fpage>655</fpage><lpage>661</lpage><pub-id pub-id-type="pmid">25285282</pub-id></element-citation></ref><ref id="B37-nutrients-10-00196"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>C.</given-names></name><name><surname>Gao</surname><given-names>D.</given-names></name><name><surname>Wilding</surname><given-names>J.</given-names></name><name><surname>Trayhurn</surname><given-names>P.</given-names></name><name><surname>Bing</surname><given-names>C.</given-names></name></person-group><article-title>Vitamin D signalling in adipose tissue</article-title><source>Br. J. Nutr.</source><year>2012</year><volume>108</volume><fpage>1915</fpage><lpage>1923</lpage><pub-id pub-id-type="doi">10.1017/S0007114512003285</pub-id><pub-id pub-id-type="pmid">23046765</pub-id></element-citation></ref><ref id="B38-nutrients-10-00196"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>N.H.</given-names></name><name><surname>Shaw</surname><given-names>S.</given-names></name><name><surname>Turner</surname><given-names>R.T.</given-names></name></person-group><article-title>Evidence that 1,25-dihydroxyvitamin D3 inhibits the hepatic production of 25-hydroxyvitamin D in man</article-title><source>J. Clin. Investig.</source><year>1984</year><volume>74</volume><fpage>1540</fpage><lpage>1544</lpage><pub-id pub-id-type="doi">10.1172/JCI111568</pub-id><pub-id pub-id-type="pmid">6332830</pub-id></element-citation></ref><ref id="B39-nutrients-10-00196"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pike</surname><given-names>J.W.</given-names></name><name><surname>Meyer</surname><given-names>M.B.</given-names></name></person-group><article-title>Regulation of mouse Cyp24a1 expression via promoter-proximal and downstream-distal enhancers highlights new concepts of 1,25-dihydroxyvitamin D(3) action</article-title><source>Arch Biochem. Biophys.</source><year>2012</year><volume>523</volume><fpage>2</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.abb.2011.12.003</pub-id><pub-id pub-id-type="pmid">22179019</pub-id></element-citation></ref><ref id="B40-nutrients-10-00196"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malluche</surname><given-names>H.H.</given-names></name><name><surname>Monier-Faugere</surname><given-names>M.C.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Fraza</surname><given-names>O.J.</given-names></name><name><surname>Charytan</surname><given-names>C.</given-names></name><name><surname>Coburn</surname><given-names>J.W.</given-names></name><name><surname>Coyne</surname><given-names>D.W.</given-names></name><name><surname>Kaplan</surname><given-names>M.R.</given-names></name><name><surname>Baker</surname><given-names>N.</given-names></name><name><surname>McCary</surname><given-names>L.C.</given-names></name><etal></etal></person-group><article-title>An assessment of cinacalcet HCL effects on bone histology in dialysis patients with secondary hyperparathyroidism</article-title><source>Clin. Nephrol.</source><year>2008</year><volume>69</volume><fpage>269</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.5414/CNP69269</pub-id><pub-id pub-id-type="pmid">18397701</pub-id></element-citation></ref><ref id="B41-nutrients-10-00196"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behets</surname><given-names>G.J.</given-names></name><name><surname>Spasovski</surname><given-names>G.</given-names></name><name><surname>Sterling</surname><given-names>L.R.</given-names></name><name><surname>Goodman</surname><given-names>W.G.</given-names></name><name><surname>Spiegel</surname><given-names>D.M.</given-names></name><name><surname>De Broe</surname><given-names>M.E.</given-names></name><name><surname>D’Haese</surname><given-names>P.C.</given-names></name></person-group><article-title>Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism</article-title><source>Kidney Int.</source><year>2015</year><volume>87</volume><fpage>846</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.1038/ki.2014.349</pub-id><pub-id pub-id-type="pmid">25337774</pub-id></element-citation></ref><ref id="B42-nutrients-10-00196"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yadav</surname><given-names>A.K.</given-names></name><name><surname>Kumar</surname><given-names>V.</given-names></name><name><surname>Kumar</surname><given-names>V.</given-names></name><name><surname>Banerjee</surname><given-names>D.</given-names></name><name><surname>Gupta</surname><given-names>K.L.</given-names></name><name><surname>Jha</surname><given-names>V.</given-names></name></person-group><article-title>The effect of vitamin D supplementation on bone metabolic markers in chronic kidney disease</article-title><source>J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res.</source><year>2017</year><pub-id pub-id-type="doi">10.1002/jbmr.3314</pub-id><pub-id pub-id-type="pmid">29044707</pub-id></element-citation></ref><ref id="B43-nutrients-10-00196"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuruta</surname><given-names>Y.</given-names></name><name><surname>Okano</surname><given-names>K.</given-names></name><name><surname>Kikuchi</surname><given-names>K.</given-names></name><name><surname>Tsuruta</surname><given-names>Y.</given-names></name><name><surname>Akiba</surname><given-names>T.</given-names></name><name><surname>Nitta</surname><given-names>K.</given-names></name></person-group><article-title>Effects of cinacalcet on bone mineral density and bone markers in hemodialysis patients with secondary hyperparathyroidism</article-title><source>Clin. Exp. Nephrol.</source><year>2013</year><volume>17</volume><fpage>120</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1007/s10157-012-0665-8</pub-id><pub-id pub-id-type="pmid">22833360</pub-id></element-citation></ref><ref id="B44-nutrients-10-00196"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lien</surname><given-names>Y.H.</given-names></name><name><surname>Silva</surname><given-names>A.L.</given-names></name><name><surname>Whittman</surname><given-names>D.</given-names></name></person-group><article-title>Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism</article-title><source>Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc.</source><year>2005</year><volume>20</volume><fpage>1232</fpage><lpage>1237</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfh829</pub-id><pub-id pub-id-type="pmid">15840675</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="nutrients-10-00196-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Study participants’ flow chart.</p></caption><graphic xlink:href="nutrients-10-00196-g001"></graphic></fig><fig id="nutrients-10-00196-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Changes in serum intact parathyroid hormone (iPTH) levels from baseline in two groups under study.</p></caption><graphic xlink:href="nutrients-10-00196-g002"></graphic></fig><table-wrap id="nutrients-10-00196-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">nutrients-10-00196-t001_Table 1</object-id><label>Table 1</label><caption><p>Demographic characteristics and baseline data of the two groups under study.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Characteristics</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CCC (<italic>n</italic> = 27)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CCP (<italic>n</italic> = 28)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Age, mean ± SD (years)</td><td align="center" valign="middle" rowspan="1" colspan="1">66.2 ± 12.8</td><td align="center" valign="middle" rowspan="1" colspan="1">65.6 ± 13.4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Male, <italic>n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">16 (59%)</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (50%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">21.94 ± 3.48</td><td align="center" valign="middle" rowspan="1" colspan="1">22.32 ± 4.14</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HD vintage (months)</td><td align="center" valign="middle" rowspan="1" colspan="1">52.8 ± 28.5</td><td align="center" valign="middle" rowspan="1" colspan="1">54.5 ± 29.6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">GN, <italic>n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (15%)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (21%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">DM, <italic>n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (48%)</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (43%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HTN, <italic>n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (19%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (14%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Others, <italic>n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (19%)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (21%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Prior calcitriol usage, <italic>n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">25 (93%)</td><td align="center" valign="middle" rowspan="1" colspan="1">24 (86%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">iPTH (pg/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">1026 ± 266</td><td align="center" valign="middle" rowspan="1" colspan="1">1018 ± 261</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">25(OH)D<sub>3</sub> (ng/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">18.2 ± 8.4</td><td align="center" valign="middle" rowspan="1" colspan="1">19.2 ± 7.4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Albumin (g/dL)</td><td align="center" valign="middle" rowspan="1" colspan="1">3.62 ± 0.41</td><td align="center" valign="middle" rowspan="1" colspan="1">3.64 ± 0.38</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Alkaline phosphatase (U/L)</td><td align="center" valign="middle" rowspan="1" colspan="1">301.2 ± 84.3</td><td align="center" valign="middle" rowspan="1" colspan="1">292.8 ± 92.4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">cCa (mg/dL)</td><td align="center" valign="middle" rowspan="1" colspan="1">10.4 ± 0.61</td><td align="center" valign="middle" rowspan="1" colspan="1">10.2 ± 0.65</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P (mg/dL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.18 ± 0.84</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.24 ± 0.76</td></tr></tbody></table><table-wrap-foot><fn><p>Data are expressed as the mean ± SD, <italic>n</italic> (%), or median (interquartile range). SD: standard deviation; BMI, body mass index; HD, hemodialysis; GN, primary glomerulonephritis; DM, diabetes mellitus; HTN, hypertension; Others, vascular or ischemic nephropathy and tubulointerstitial nephritis; iPTH, parathyroid hormone; 25(OH)D<sub>3</sub>, 25-Hydroxyvitamin D; cCa, albumin-corrected calcium; P, phosphorus. CCC: Cinacalcet + Calcitriol + Cholecalciferol; CCP: Cinacalcet + Calcitriol + Placebo.</p></fn></table-wrap-foot></table-wrap><table-wrap id="nutrients-10-00196-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">nutrients-10-00196-t002_Table 2</object-id><label>Table 2</label><caption><p>Serum biochemistry parameters change among the two groups under study.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Parameters</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">CCC (<italic>n</italic> = 27)</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">CCP (<italic>n</italic> = 28)</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Before</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">After</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic> Value</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Before</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">After</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic> Value</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">iPTH (pg/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">1026 ± 266</td><td align="center" valign="middle" rowspan="1" colspan="1">265.8 ± 47.0</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.01</td><td align="center" valign="middle" rowspan="1" colspan="1">1018 ± 261</td><td align="center" valign="middle" rowspan="1" colspan="1">326.1 ± 77.3</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.01</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">25(OH)D<sub>3</sub> (ng/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">18.2 ± 8.4</td><td align="center" valign="middle" rowspan="1" colspan="1">37.4 ± 9.6</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.01</td><td align="center" valign="middle" rowspan="1" colspan="1">19.2 ± 7.4</td><td align="center" valign="middle" rowspan="1" colspan="1">23.4 ± 7.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.46</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Alk-P (U/L)</td><td align="center" valign="middle" rowspan="1" colspan="1">301.2 ± 84.3</td><td align="center" valign="middle" rowspan="1" colspan="1">121.4 ± 48.6</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.01</td><td align="center" valign="middle" rowspan="1" colspan="1">292.8 ± 92.4</td><td align="center" valign="middle" rowspan="1" colspan="1">148.4 ± 58.6</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.01</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">BAP (U/L)</td><td align="center" valign="middle" rowspan="1" colspan="1">42.2 ± 8.4</td><td align="center" valign="middle" rowspan="1" colspan="1">23.6 ± 7.2</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.01</td><td align="center" valign="middle" rowspan="1" colspan="1">44.5 ± 9.2</td><td align="center" valign="middle" rowspan="1" colspan="1">28.62 ± 6.8</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.01</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TRACP-5b (U/L)</td><td align="center" valign="middle" rowspan="1" colspan="1">7.8 ± 3.8</td><td align="center" valign="middle" rowspan="1" colspan="1">2.4 ± 1.6</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.01</td><td align="center" valign="middle" rowspan="1" colspan="1">7.6 ± 3.7</td><td align="center" valign="middle" rowspan="1" colspan="1">3.2 ± 1.8</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.01</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Albumin</td><td align="center" valign="middle" rowspan="1" colspan="1">3.62 ± 0.41</td><td align="center" valign="middle" rowspan="1" colspan="1">3.72 ± 0.39</td><td align="center" valign="middle" rowspan="1" colspan="1">0.08</td><td align="center" valign="middle" rowspan="1" colspan="1">3.64 ± 0.38</td><td align="center" valign="middle" rowspan="1" colspan="1">3.86 ± 0.41</td><td align="center" valign="middle" rowspan="1" colspan="1">0.24</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">cCa (mg/dL)</td><td align="center" valign="middle" rowspan="1" colspan="1">10.4 ± 0.61</td><td align="center" valign="middle" rowspan="1" colspan="1">9.16 ± 0.54</td><td align="center" valign="middle" rowspan="1" colspan="1">0.26</td><td align="center" valign="middle" rowspan="1" colspan="1">10.2 ± 0.65</td><td align="center" valign="middle" rowspan="1" colspan="1">9.24 ± 0.61</td><td align="center" valign="middle" rowspan="1" colspan="1">0.41</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P (mg/dL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.18 ± 0.84</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.01 ± 0.54</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.49</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.24 ± 0.76</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.14 ± 0.62</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.77</td></tr></tbody></table><table-wrap-foot><fn><p>iPTH, parathyroid hormone; 25(OH)D3, 25-Hydroxyvitamin D; Alk-P, alkaline phosphatase; BAP, bone alkaline phosphatase; TRACP-5b, tartrate-resistant acid phosphatase 5b; cCa, albumin-corrected calcium; P, phosphorus.</p></fn></table-wrap-foot></table-wrap><table-wrap id="nutrients-10-00196-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">nutrients-10-00196-t003_Table 3</object-id><label>Table 3</label><caption><p>Serum iPTH levels and mean iPTH change from baseline in the two groups under study.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Week</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CCC (<italic>n</italic> = 27)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CCP (<italic>n</italic> = 28)</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1"><italic>p</italic> Value *</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CCC (<italic>n</italic> = 27)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CCP (<italic>n</italic> = 28)</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1"><italic>p</italic> Value *</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">iPTH (pg/mL)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">iPTH (pg/mL)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">△iPTH (pg/mL)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">△iPTH (pg/mL)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Baseline</td><td align="center" valign="middle" rowspan="1" colspan="1">1026.1 ± 266.1</td><td align="center" valign="middle" rowspan="1" colspan="1">1018.0 ± 260.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.909</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4th week</td><td align="center" valign="middle" rowspan="1" colspan="1">1077.9 ± 274.8</td><td align="center" valign="middle" rowspan="1" colspan="1">1066.7 ± 274.2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.881</td><td align="center" valign="middle" rowspan="1" colspan="1">51.8 ± 159.1</td><td align="center" valign="middle" rowspan="1" colspan="1">49.0 ± 116.2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.942</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">8th week</td><td align="center" valign="middle" rowspan="1" colspan="1">961.7 ± 243.0</td><td align="center" valign="middle" rowspan="1" colspan="1">954.4 ± 236.6</td><td align="center" valign="middle" rowspan="1" colspan="1">0.910</td><td align="center" valign="middle" rowspan="1" colspan="1">−64.2 ± 39.7</td><td align="center" valign="middle" rowspan="1" colspan="1">−63.2 ± 39.7</td><td align="center" valign="middle" rowspan="1" colspan="1">0.925</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">12th week</td><td align="center" valign="middle" rowspan="1" colspan="1">722.5 ± 247.3</td><td align="center" valign="middle" rowspan="1" colspan="1">764.5 ± 191.0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.483</td><td align="center" valign="middle" rowspan="1" colspan="1">−303.5 ± 151.2</td><td align="center" valign="middle" rowspan="1" colspan="1">−253.2 ± 75.9</td><td align="center" valign="middle" rowspan="1" colspan="1">0.123</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">16th week</td><td align="center" valign="middle" rowspan="1" colspan="1">497.6 ± 182.5</td><td align="center" valign="middle" rowspan="1" colspan="1">566.1 ± 153.7</td><td align="center" valign="middle" rowspan="1" colspan="1">0.137</td><td align="center" valign="middle" rowspan="1" colspan="1">−528.5 ± 148.1</td><td align="center" valign="middle" rowspan="1" colspan="1">−451.6± 116.0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.036</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">20th week</td><td align="center" valign="middle" rowspan="1" colspan="1">336.4 ± 124.1</td><td align="center" valign="middle" rowspan="1" colspan="1">404.4 ± 107.0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.034</td><td align="center" valign="middle" rowspan="1" colspan="1">−689.6 ± 172.9</td><td align="center" valign="middle" rowspan="1" colspan="1">−613.3 ± 161.0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.096</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24th week</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">265.8 ± 47.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">326.1 ± 77.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−686.8 ± 212.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.252</td></tr></tbody></table><table-wrap-foot><fn><p>* <italic>t</italic>-test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="nutrients-10-00196-t004" orientation="portrait" position="float"><object-id pub-id-type="pii">nutrients-10-00196-t004_Table 4</object-id><label>Table 4</label><caption><p>Serum iPTH levels changes in patients with baseline 25(OH)D3 &lt; 12.5 ng/mL.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Week</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CCC (<italic>n</italic> = 6)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CCP (<italic>n</italic> = 5)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic> Value</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Baseline</td><td align="center" valign="middle" rowspan="1" colspan="1">1034.6 ± 282.4</td><td align="center" valign="middle" rowspan="1" colspan="1">1124.2 ± 284.6</td><td align="center" valign="middle" rowspan="1" colspan="1">0.612</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4th week</td><td align="center" valign="middle" rowspan="1" colspan="1">1038.4 ± 284.8</td><td align="center" valign="middle" rowspan="1" colspan="1">1106.7 ± 274.2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.697</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">8th week</td><td align="center" valign="middle" rowspan="1" colspan="1">864.3 ± 262.1</td><td align="center" valign="middle" rowspan="1" colspan="1">965.4 ± 266.4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.543</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">12th week</td><td align="center" valign="middle" rowspan="1" colspan="1">486.5 ± 203.9</td><td align="center" valign="middle" rowspan="1" colspan="1">841.5 ± 209.1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.024</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">16th week</td><td align="center" valign="middle" rowspan="1" colspan="1">354.2 ± 153.5</td><td align="center" valign="middle" rowspan="1" colspan="1">642.2 ± 193.7</td><td align="center" valign="middle" rowspan="1" colspan="1">0.022</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">20th week</td><td align="center" valign="middle" rowspan="1" colspan="1">265.7 ± 108.3</td><td align="center" valign="middle" rowspan="1" colspan="1">482.3 ± 168.8</td><td align="center" valign="middle" rowspan="1" colspan="1">0.029</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24th week</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">225.5 ± 34.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">384.6 ± 136.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.021</td></tr></tbody></table></table-wrap><table-wrap id="nutrients-10-00196-t005" orientation="portrait" position="float"><object-id pub-id-type="pii">nutrients-10-00196-t005_Table 5</object-id><label>Table 5</label><caption><p>Mean dose of intravenous calcitriol (μg/week) during the course of treatment.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Week</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CCC (<italic>n</italic> = 27)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CCP (<italic>n</italic> = 28)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Baseline</td><td align="center" valign="middle" rowspan="1" colspan="1">3 μg/week</td><td align="center" valign="middle" rowspan="1" colspan="1">3 μg/week</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4th week</td><td align="center" valign="middle" rowspan="1" colspan="1">3 μg/week</td><td align="center" valign="middle" rowspan="1" colspan="1">3 μg/week</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">8th week</td><td align="center" valign="middle" rowspan="1" colspan="1">3 μg/week</td><td align="center" valign="middle" rowspan="1" colspan="1">3 μg/week</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">12th week</td><td align="center" valign="middle" rowspan="1" colspan="1">2.67 μg/week</td><td align="center" valign="middle" rowspan="1" colspan="1">3 μg/week</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">16th week</td><td align="center" valign="middle" rowspan="1" colspan="1">2.22 μg/week</td><td align="center" valign="middle" rowspan="1" colspan="1">2.79 μg/week</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">20th week</td><td align="center" valign="middle" rowspan="1" colspan="1">1.44 μg/week</td><td align="center" valign="middle" rowspan="1" colspan="1">2.57 μg/week</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24th week</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.56 μg/week</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.25 μg/week</td></tr></tbody></table></table-wrap><table-wrap id="nutrients-10-00196-t006" orientation="portrait" position="float"><object-id pub-id-type="pii">nutrients-10-00196-t006_Table 6</object-id><label>Table 6</label><caption><p>Number of study patients achieving primary and secondary outcomes in the two groups under study.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><bold>Primary Outcome</bold></td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><bold>12th Week</bold></td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><bold>16th Week</bold></td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><bold>20th Week</bold></td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><bold>24th Week</bold></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">iPTH ≤ 300 pg/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CCC (<italic>n</italic> = 27)</td><td align="center" valign="middle" rowspan="1" colspan="1">3/27 (11.1%)</td><td align="center" valign="middle" rowspan="1" colspan="1">8/27 (29.6%)</td><td align="center" valign="middle" rowspan="1" colspan="1">15/27 (55.6%)</td><td align="center" valign="middle" rowspan="1" colspan="1">22/27 (81.5%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CCP (<italic>n</italic> = 28)</td><td align="center" valign="middle" rowspan="1" colspan="1">2/28 (7.1%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3/28 (10.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4/28 (14.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">7/28 (25%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic> = 1.000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic> = 0.270</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic> = 0.046</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic> = 0.033</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Secondary Outcome</bold></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>12th Week</bold></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>16th Week</bold></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>20th Week</bold></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>24th Week</bold></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">25(OH)D<sub>3</sub> ≥ 30 ng/dL</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CCC (<italic>n</italic> = 27)</td><td align="center" valign="middle" rowspan="1" colspan="1">21/27 (77.8%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">24/27 (88.9%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CCP (<italic>n</italic> = 28)</td><td align="center" valign="middle" rowspan="1" colspan="1">2/28 (7.1%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">3/28 (10.7%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic> = 0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic> = 0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">↑ FN-BMD &gt; 10%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CCC (<italic>n</italic> = 27)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">13/27 (40%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CCP (<italic>n</italic> = 28)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">5/28 (6.7%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic> = 0.150</td></tr></tbody></table></table-wrap><table-wrap id="nutrients-10-00196-t007" orientation="portrait" position="float"><object-id pub-id-type="pii">nutrients-10-00196-t007_Table 7</object-id><label>Table 7</label><caption><p>Bone mineral density (BMD) changes after 24 weeks of treatment in the two groups under study.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Parameters</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">CCC (<italic>n</italic> = 27)</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">CCP (<italic>n</italic> = 28)</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Before</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">After</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic> Value</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Before</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">After</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic> Value</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">FN-BMD (g/cm<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.57 ± 0.04</td><td align="center" valign="middle" rowspan="1" colspan="1">0.67 ± 0.07</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">0.58 ± 0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">0.62 ± 0.06</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.05</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">FN-T score</td><td align="center" valign="middle" rowspan="1" colspan="1">−2.1 ± 0.5</td><td align="center" valign="middle" rowspan="1" colspan="1">−1.2 ± 0.4</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">−2.2 ± 0.6</td><td align="center" valign="middle" rowspan="1" colspan="1">−1.8 ± 0.5</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.05</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LS-BMD (g/cm<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.91 ± 0.09</td><td align="center" valign="middle" rowspan="1" colspan="1">0.96 ± 0.10</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">0.89 ± 0.07</td><td align="center" valign="middle" rowspan="1" colspan="1">0.94 ± 0.08</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.05</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LS-T score</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−0.7 ± 0.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−0.6 ± 0.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.627</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−0.8 ± 0.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−0.7 ± 0.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.568</td></tr></tbody></table><table-wrap-foot><fn><p>Data are expressed as mean ± standard error.</p></fn></table-wrap-foot></table-wrap></floats-group></article>